US20100092571A1 - Microcapsules having multiple shells and method for the preparation thereof - Google Patents
Microcapsules having multiple shells and method for the preparation thereof Download PDFInfo
- Publication number
- US20100092571A1 US20100092571A1 US12/642,303 US64230309A US2010092571A1 US 20100092571 A1 US20100092571 A1 US 20100092571A1 US 64230309 A US64230309 A US 64230309A US 2010092571 A1 US2010092571 A1 US 2010092571A1
- Authority
- US
- United States
- Prior art keywords
- shell
- microcapsules
- shells
- core
- gelatine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 171
- 238000000034 method Methods 0.000 title abstract description 48
- 238000002360 preparation method Methods 0.000 title description 3
- 229920000159 gelatin Polymers 0.000 claims description 61
- 235000019322 gelatine Nutrition 0.000 claims description 61
- 239000001828 Gelatine Substances 0.000 claims description 60
- 229920000642 polymer Polymers 0.000 claims description 35
- 229920000388 Polyphosphate Polymers 0.000 claims description 22
- 239000001205 polyphosphate Substances 0.000 claims description 22
- 235000011176 polyphosphates Nutrition 0.000 claims description 22
- 229920000615 alginic acid Polymers 0.000 claims description 21
- 229940072056 alginate Drugs 0.000 claims description 20
- 235000010443 alginic acid Nutrition 0.000 claims description 20
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 19
- 239000003921 oil Substances 0.000 claims description 18
- 238000005054 agglomeration Methods 0.000 claims description 13
- 230000002776 aggregation Effects 0.000 claims description 13
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 239000001993 wax Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 239000004971 Cross linker Substances 0.000 claims description 8
- 229920000084 Gum arabic Polymers 0.000 claims description 7
- 235000010489 acacia gum Nutrition 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 7
- 239000000205 acacia gum Substances 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- -1 whey proteins Proteins 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229960000292 pectin Drugs 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 108010011756 Milk Proteins Proteins 0.000 claims description 2
- 108010073771 Soybean Proteins Proteins 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 235000021239 milk protein Nutrition 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 229940001941 soy protein Drugs 0.000 claims description 2
- 241000978776 Senegalia senegal Species 0.000 claims 2
- 239000011257 shell material Substances 0.000 abstract description 118
- 239000000203 mixture Substances 0.000 description 71
- 239000011162 core material Substances 0.000 description 64
- 230000008569 process Effects 0.000 description 37
- 239000000243 solution Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000000126 substance Substances 0.000 description 26
- 238000011068 loading method Methods 0.000 description 22
- 239000008367 deionised water Substances 0.000 description 21
- 229910021641 deionized water Inorganic materials 0.000 description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 18
- 238000013019 agitation Methods 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 239000000839 emulsion Substances 0.000 description 17
- 239000002245 particle Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 12
- 238000001816 cooling Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 235000010378 sodium ascorbate Nutrition 0.000 description 11
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 10
- 238000010979 pH adjustment Methods 0.000 description 10
- 229960005055 sodium ascorbate Drugs 0.000 description 10
- 235000019830 sodium polyphosphate Nutrition 0.000 description 10
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 9
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000006057 Non-nutritive feed additive Substances 0.000 description 7
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 7
- 238000005354 coacervation Methods 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 238000001694 spray drying Methods 0.000 description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 6
- 235000010413 sodium alginate Nutrition 0.000 description 6
- 239000000661 sodium alginate Substances 0.000 description 6
- 229940005550 sodium alginate Drugs 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 229940088623 biologically active substance Drugs 0.000 description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 5
- 235000021323 fish oil Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000011732 tocopherol Substances 0.000 description 5
- 229930003799 tocopherol Natural products 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 108060008539 Transglutaminase Proteins 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000007764 o/w emulsion Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000019149 tocopherols Nutrition 0.000 description 4
- 102000003601 transglutaminase Human genes 0.000 description 4
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 4
- TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000007863 gel particle Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229940075999 phytosterol ester Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- LGHXTTIAZFVCCU-SSVNFBSYSA-N (2E,4E,6E,8E)-octadeca-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O LGHXTTIAZFVCCU-SSVNFBSYSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241001365823 Anchoviella guianensis Species 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000165918 Eucalyptus papuana Species 0.000 description 1
- 241000590913 Euploea core Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000665629 Linum flavum Species 0.000 description 1
- 241001417902 Mallotus villosus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000736062 Scomber scombrus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000320 mechanical mixture Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/20—After-treatment of capsule walls, e.g. hardening
- B01J13/22—Coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
- A23L27/72—Encapsulation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
- Y10T428/2985—Solid-walled microcapsule from synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2989—Microcapsule with solid core [includes liposome]
Definitions
- This invention relates to microcapsules having multiple shells, to methods of preparing microcapsules and to their use.
- Microcapsules are small particles of solids, or droplets of liquids, inside a thin coating of a shell material such as starch, gelatine, lipids, polysaccharides, wax or polyacrylic acids. They are used, for example, to prepare liquids as free-flowing powders or compressed solids, to separate reactive materials, to reduce toxicity, to protect against oxidation and/or to control the rate of release of a substance such as an enzyme, flavour, a nutrient, a drug, etc.
- a shell material such as starch, gelatine, lipids, polysaccharides, wax or polyacrylic acids. They are used, for example, to prepare liquids as free-flowing powders or compressed solids, to separate reactive materials, to reduce toxicity, to protect against oxidation and/or to control the rate of release of a substance such as an enzyme, flavour, a nutrient, a drug, etc.
- a microcapsule would have good mechanical strength (e.g. resistance to rupture) and the microcapsule shell would provide a good barrier to oxidation, etc.
- a typical approach to meeting these requirements is to increase the thickness of the microcapsule wall. But this results in an undesirable reduction in the loading capacity of the microcapsule. That is, the “payload” of the microcapsule, being the mass of the loading substance encapsulated in the microcapsule divided by the total mass of the microcapsule, is low.
- the typical payload of such “single-core” microcapsules made by spray drying an emulsion is in the range of about 25-50%.
- Multi-core microcapsules are usually formed by spray drying an emulsion of core material such that the shell material coats individual particles of core material, which then aggregate and form a cluster.
- a typical multi-core microcapsule is depicted in prior art FIG. 1 .
- Multi-core microcapsule 10 contains a plurality of cores 12 .
- the cores 12 take the form of entrapped particles of solids or of liquid droplets dispersed throughout a relatively continuous matrix of shell material 14 .
- the shell material is poorly distributed.
- many of the cores 12 are very close to the surface 16 of the microcapsule. The cores at the surface are therefore not well protected against rupture or from oxidation.
- microcapsules therefore either have a poor payload, or fail to adequately contain and protect the loading substance deposited therein. Moreover, because these microcapsules are generally prepared in a single step, it is difficult to incorporate multiple functionalities, such as oxidation resistance, moisture resistance and taste masking into a single microcapsule.
- the invention provides a multi-core microcapsule comprising: (a) an agglomeration of primary microcapsules, each primary microcapsule comprising a core and a first shell surrounding the core; (b) a second shell surrounding the agglomeration; and (c) a third shell surrounding the second shell; at least one of the first, second and third shells comprising a complex coacervate.
- the invention provides a single-core microcapsule comprising: (a) a core; (b) a first shell surrounding the core; and (c) a second shell surrounding the first shell; at least one of the first and second shells comprising a complex coacervate.
- all of the shells comprise a complex coacervate, which may be the same or different for each of the shells. Additional shells, e.g. from 1 to 20, may be added to further strengthen the microcapsule.
- the invention provides a process for making a microcapsule having a plurality of shells, the process comprising:
- FIG. 1 depicts a typical prior art multi-core microcapsule.
- FIGS. 2 and 3 depict embodiments of the invention in which multi-core microcapsules are provided having multiple shells.
- FIGS. 4 and 5 depict embodiments of the invention in which single-core microcapsules are provided having multiple shells.
- FIG. 6 is a photomicrograph of multi-core microcapsules prepared with a one-step process (62% payload), prepared for purposes of comparison.
- FIG. 7 is a photomicrograph of multi-core microcapsules prepared with a two-step process in accordance with the invention (59% payload).
- FIG. 8 is a photomicrograph of multi-core microcapsules prepared with a two-step process in accordance with the invention in which alginate is incorporated in the outer shell (53% payload).
- FIG. 9 is a photomicrograph of multi-core microcapsules prepared with a three-step process in which lipids and alginate are incorporated in an inner shell while gelatine and polyphosphate forms an outer shell.
- FIG. 10 is a photomicrograph of multi-core microcapsules prepared with a two-step process in which lipids and alginate are incorporated in the second shell.
- any core material that may be encapsulated in microcapsules is useful in the invention. Indeed, in certain embodiments, commercially available microcapsules may be obtained and then further processed according to the processes of the invention.
- the core material may be virtually any substance that is not entirely soluble in the aqueous solution.
- the core is a solid, a hydrophobic liquid, or a mixture of a solid and a hydrophobic liquid.
- the core is more preferably a hydrophobic liquid, such as grease, oil or a mixture thereof.
- Typical oils may be fish oils, vegetable oils, mineral oils, derivatives thereof or mixtures thereof.
- the loading substance may comprise a purified or partially purified oily substance such as a fatty acid, a triglyceride or a mixture thereof.
- Omega-3 fatty acids such as o-linolenic acid (18:3n3), octadecatetraenoic acid (18:4n3), eicosapentaenoic acid (20:5n3) (EPA) and docosahexaenoic acid (22:6n3) (DHA), and derivatives thereof and mixtures thereof, are preferred. Many types of derivatives are well known to one skilled in the art.
- esters such as phytosterol esters, branched or unbranched C 1 -C 30 alkyl esters, branched or unbranched C 2 -C 30 alkenyl esters or branched or unbranched C 3 -C 30 cycloalkyl esters, in particular phytosterol esters and C 1 -C 6 alkyl esters.
- Preferred sources of oils are oils derived from aquatic organisms (e.g. anchovies, capelin, Atlantic cod, Atlantic herring, Atlantic mackerel, Atlantic menhaden, salmonids, sardines, shark, tuna, etc) and plants (e.g. flax, vegetables, algae, etc).
- the core may or may not be a biologically active substance such as a tocopherol, antioxidant or vitamin
- the microcapsules of the present invention are particularly suited for biologically active substances, for example, drugs, nutritional supplements, flavours, antioxidants or mixtures thereof.
- Coacervation is a phase separation phenomenon, in which a homogenous polymer solution is converted into two phases.
- One is a polymer-rich phase, called a coacervate.
- the other is a polymer-poor phase, i.e., solvent.
- Complex coacervation is caused by the interaction of two oppositely charged polymers.
- a positively charged polymer component “A” interacts with a negatively charged polymer component “B”.
- positively charged type A gelatine (“component A”) forms complex coacervates with negatively charged polyphosphate (“component B”).
- component A positively charged type A gelatine
- component B negatively charged polyphosphate
- Other systems that have been studied are gelatine/gum Acacia, gelatine/pectin, gelatine/carboxymethyl guar gum and whey protein/gum arabic.
- Component A is preferably gelatine type A, chitosan, etc., although other polymers are also contemplated as component A.
- Component B is preferably gelatine type B, polyphosphate, gum arabic, alginate, carrageenan, pectin, carboxymethylcellulose, or a mixture thereof.
- complex coacervation depends on other factors such as molecular weight of the polymers and their ratio, ionic strength, pH and temperature of the medium ( J. Microencapsulation, 2003, Vol. 20, No. 2: 203-210).
- the molar ratio of component A:component B that is used depends on the type of components but is typically from 1:5 to 15:1.
- the molar ratio of component A:component B is preferably 8:1 to 12:1; when gelatine type A and gelatine type B are used as components A and B respectively, the molar ratio of component A:component B is preferably 2:1 to 1:2; and when gelatine type A and alginate are used as components A and B respectively, the molar ratio of component A:component B is preferably 3:1 to 5:1.
- One suitable process of microencapsulation using complex coacervation comprises three steps: 1) dispersing the loading substance into a system of at least one of the polymers for the complex coacervate; 2) forming shells by deposition of coacervates which derive from the polymeric components under controlled conditions of temperature, pH, concentration of colloids, mixing speed etc.; and 3) hardening of the shells by crosslinking of the coacervates deposited on microcapsules ( Ullmann's Encyclopedia of Industrial Chemistry 6 th edition. 2001, Vol. A16. pp. 575-588).
- any shells that do not comprise complex coacervates may be formed of any material that can form an additional shell around the microcapsule.
- the additional shell material typically comprises at least one polymer component.
- polymer components include, but are not limited to, proteins, e.g. gelatines, soy proteins, whey proteins, and milk proteins, polyphosphate, polysaccharides and mixtures thereof.
- Preferred polymer components are gelatine A, gelatine B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin, cellulose or derivatives of cellulose such as carboxymethylcellulose (CMC) or a mixture thereof.
- a particularly preferred form of gelatine type A has a Bloom strength of 50-350, more preferably a Bloom strength of about 275.
- the shell material can also comprise lipids, such as waxes, fatty acids and oils, etc. to provide desired functionalities.
- lipids such as waxes, fatty acids and oils, etc.
- the incorporation of lipids into the shell material improves the impermeability of the shell to water and oxygen.
- a preferred lipid for this purpose is beeswax. These lipids may be in solid, semi-solid or liquid form.
- Processing aids may be included in the shell material. Processing aids may be used for a variety of reasons. For example, they may be used to promote agglomeration of primary microcapsules when forming multi-core microcapsules, control microcapsule size and shape and/or to act as an antioxidant. Antioxidant properties are useful both during the process (e.g. during coacervation and/or spray drying) and in the microcapsules after they are formed (e.g. to extend shelf-life of loading substances which are readily oxidized, etc). Preferably a small number of processing aids that perform a large number of functions are used.
- ascorbic acid or a salt thereof may be used to promote agglomeration of the primary microcapsules, to control microcapsule size and shape and to act as an antioxidant.
- the ascorbic acid or salt thereof is preferably used in an amount of about 100 ppm to about 10,000 ppm, more preferably about 1000 ppm to about 5000 ppm relative to the batch size (i.e., the total weight).
- a salt of ascorbic acid, such as sodium or potassium ascorbate is particularly preferred in this capacity.
- Other processing aids include, without limitation, buffering acids and/or their salts such as phosphoric acid, acetic acid, citric acid, and the like.
- microcapsules of the invention have a structure generally as depicted in FIG. 2 .
- FIG. 2 depicts a multi-core microcapsule prepared according to a multi-step process of the invention.
- Primary microcapsules comprise cores 18 (i.e. the loading substance) surrounded by first shells 20 .
- the primary microcapsules agglomerate and the space 22 between them is usually at least partly filled by additional shell material of same composition as first shell 20 , although there may be voids between some of the primary microcapsules.
- the agglomeration of primary microcapsules is surrounded by a second shell 24 .
- Multi-core microcapsules comprising second shell 24 may be prepared according to the processes described herein and exemplified in the examples or by generally the same techniques that are described in Applicant's co-pending U.S. patent application Ser. No. 10/120,621 filed Apr. 11, 2002, corresponding to International Application No. PCT/CA2003/000520 filed Apr. 8, 2003, the disclosures of both of which are incorporated herein by reference.
- These multi-core microcapsules are particularly useful because the foam-like structure of primary microcapsules, supported by additional shell material in space 22 and surrounded by second shell 24 is an extremely strong, rupture-resistant structure that has a high payload i.e.
- the ratio of the total mass of the cores to the total mass of the multi-core microcapsule is very high, e.g. at least 50, 55, 60, 65, 70, 75, 80, 85, 90% or higher.
- This is called a “one-step” process when shells 20 and 24 are of the same composition and formed in a single step.
- the process involves two steps.
- multicore microcapsules may also be used as starting materials.
- An example is the DriphormTM Hi-DHATM microencapsulated tuna oil, manufactured by Nu-Mega Ingredients Pty. Ltd., Queensland, AU.
- a three-step process takes place when a third shell 26 is formed on the multi-core microcapsule.
- Third shell 26 further strengthens the microcapsule and can be advantageously used to provide a shell having properties different from those of shell 24 .
- third shell 26 different polymer components can be incorporated into third shell 26 .
- lipids may be incorporated into shell 26 to increase moisture or oxygen impermeability or the like. These properties might instead be incorporated into second shell 24 rather than third shell 26 (or also into second shell 24 as well as into third shell 26 ), depending on the requirements for a particular purpose.
- Additional shells may be formed around third shell 26 , by the methods and techniques of the invention. For instance, N additional shells could be added, wherein N is an integer from 1 to 20.
- At least one of shells 20 , 24 and 26 and of any additional shells comprises a complex coacervate, as described above.
- at least two of the shells comprise a complex coacervate.
- all of the shells comprise a complex coacervate.
- the following shells may comprise complex coacervates: (a) shell 20 ; (b) shell 24 ; (c) shell 26 ; (d) shells 20 and 24 ; (e) shells 20 and 26 ; (f) shells 24 and 26 ; or (g) shells 20 , 24 and 26 .
- Additional shells also preferably comprise a complex coacervate.
- the primary microcapsules typically have an average diameter of about 40 nm to about 10 ⁇ m, more particularly from about 0.1 ⁇ m to about 5 ⁇ m, even more particularly an average diameter of about 1-2 ⁇ m.
- the finished multi-core microcapsule, i.e. including third shell 26 usually has an average diameter from about 1 ⁇ m to about 2000 ⁇ m, more typically from about 20 ⁇ m to about 1000 ⁇ m, more particularly from about 20 ⁇ m to about 100 ⁇ m and even more particularly from about 50 ⁇ m to about 100 ⁇ m.
- second shell 24 and third shell 26 are depicted as discrete layers. This will be the case if the shells are formed of the different shell materials. In that case, even if they do not differ in appearance, they will have a different composition and can be represented as discrete, distinct layers. But if second shell 24 and third shell 26 are formed of the same shell material, they may, as shown in FIG. 3 , merge to form a single, continuous layer, having the combined thickness of second shell 24 and third shell 26 . As shown in FIG. 3 , when the second and third shells are of the same composition, there may be no discrete boundary separating them. This would be true also in microcapsules of the invention having fourth or additional shells that are of the same composition as the preceding shell.
- the invention is also useful in the preparation of single-core microcapsules having multiple shells.
- Single-core microcapsules useful as starting materials are commercially available. Examples include microencapsulated flavours by Givaudan Flavors Corp., Cincinnati, Ohio, USA, and microencapsulated minerals and vitamins by Watson Food Co. Inc., West Haven, Conn., USA. Alternatively, they can be made by complex coacervation processes as described herein, e.g. by preparing primary microcapsules without a further agglomeration step.
- FIG. 4 depicts a single-core microcapsule having multiple shells in accordance with the invention. Core 18 is surrounded by a first shell 20 and a second shell 24 . Additional shells, not shown in FIG. 4 , may be formed around second shell 24 , by the methods and techniques of the invention. For instance, N additional shells could be added, wherein N is an integer from 1 to 20.
- shells 20 and 24 of single-core microcapsules may be of the same or different composition. At least one of shells 20 and 24 and of any additional shells comprises complex coacervates as described above. Preferably, at least two of the shells comprise a complex coacervate. Even more preferably all of the shells comprise a complex coacervate. For instance, the following shells may comprise complex coacervates: (a) shell 20 ; (b) shell 24 ; or (c) shells 20 and 24 . Additional shells also preferably comprise complex coacervates.
- Single-core microcapsules may be as large as multi-core microcapsules.
- the exterior diameter of second shell 24 in the single-core microcapsule of FIG. 4 may be from about 1 ⁇ m to about 2000 ⁇ m. More typically it will be from about 20 ⁇ m to about 1000 ⁇ m, more particularly from about 20 ⁇ m to about 100 ⁇ m and even more particularly from about 50 ⁇ m to about 100 ⁇ m.
- first shell 20 and second shell 24 (and any additional shell) of the single-core multicapsule may merge to form a single continuous layer as depicted in FIG. 5 . This may be done in a one-step process.
- Multi-core microcapsules to which additional shells may be added by the processes of the invention may be obtained from commercial sources.
- multi-core microcapsules prepared in accordance with applicant's co-pending U.S. patent application Ser. No. 10/120,621 filed Apr. 11, 2002, corresponding to International Application No. PCT/CA2003/000520 filed Apr. 8, 2003, the disclosures of both of which are incorporated herein by reference, are used.
- Such microcapsules can be prepared e.g. by a one step process as follows.
- An aqueous mixture of a loading substance i.e.
- the aqueous mixture may be a mechanical mixture, a suspension or an emulsion.
- the aqueous mixture is preferably an emulsion of the loading material and the polymer components.
- a first polymer component is provided in aqueous solution, preferably together with processing aids, such as antioxidants.
- a loading substance may then be dispersed into the aqueous mixture, for example, by using a homogenizer. If the loading substance is a hydrophobic liquid, an emulsion is formed in which a fraction of the first polymer component begins to deposit around individual droplets of loading substance to begin the formation of primary shells. If the loading substance is a solid particle, a suspension is formed in which a fraction of the first polymer component begins to deposit around individual particles to begin the formation of primary shells. At this point, another aqueous solution of a second polymer component may be added to the aqueous mixture.
- Droplets or particles of the loading substance in the aqueous mixture preferably have an average diameter of less than 100 ⁇ m, more preferably less than 50 ⁇ m, even more preferably less than 25 ⁇ m. Droplets or particles of the loading substance having an average diameter less than 10 ⁇ m or less than 5 ⁇ m or less than 3 ⁇ m or less than 1 ⁇ m may be used. Particle size may be measured using any typical equipment known in the art, for example, a CoulterTM LS230 Particle Size Analyzer, Miami, Fla., USA.
- the amount of the polymer components of the shell material provided in the aqueous mixture is typically sufficient to form both the primary and outer shells of microcapsules.
- the loading substance is provided in an amount of from about 1% to about 15% by weight of the aqueous mixture, more preferably from about 3% to about 8% by weight, and even more preferably about 6% by weight.
- the pH, temperature, concentration, mixing speed or a combination thereof is then adjusted to accelerate the formation of the primary shells of complex coacervate around the droplets or particles of the loading substance to form primary microcapsules.
- agglomeration of the primary microcapsules will take place to form discrete clumps at desired size and shape.
- pH is an expression of the concentration of hydrogen ions in solution. Such ions affect the ionization equilibria of the component A and B polymers involved in complex coacervation and thus the formation of complex coacervates.
- the pH is adjusted so that the component A polymer will bear a net positive charge and the component B polymer will bear a net negative charge. Hence, the pH adjustment depends on the type of shell material to be used.
- gelatine type A when gelatine type A is a polymer component, the gelatine molecules have nearly equal positive and negative charges (i.e. zero net polarity change) at their point of zero charge (pzc) around pH 9-10. Only when the solution pH is lower than the pzc value, will the polymer bear a net positive charge, which interacts with the negatively charged component B (e.g. gum arabic, polyphosphate, alginate, etc.).
- negatively charged component B e.g. gum arabic, polyphosphate, alginate, etc.
- the pH is preferably adjusted to a value from 3.5-5.0, more preferably from 4.0-5.0. Much outside this range, the gelatine-based complex tends to form gels upon cooling rather than a shell on the microcapsules. If the pH of the mixture starts in the desired range, then little or no pH adjustment is required.
- the molar ratio of components A and B is adjusted to favour formation of shells on the microcapsules rather than merely the formation of gel particles in solution. Suitable molar ratios are discussed above under the heading “Shell Material”.
- the concentration of components A and B in the aqueous mixture may also affect the formation of complex coacervates and can be adjusted accordingly.
- the total concentration of components A and B varies from 1% to 20%, preferably 2-10%, and more preferably 3-6% by weight of the aqueous mixture.
- the concentration of gelatine type A is preferably from 1-15% by weight of the aqueous mixture, more preferably 2-6% by weight and even more preferably 2-4% by weight.
- polyphosphate when polyphosphate is used as component B, its concentration in the aqueous mixture is preferably 0.01-0.65% by weight of the aqueous mixture, more preferably 0.13-0.17% by weight, even more preferably 0.13-0.26% by weight.
- the initial temperature of the aqueous mixture is preferably set to a value of from about 40° C. to about 60° C., more preferably at about 50° C.
- Mixing speed influences the deposition of complex coacervates on the surface of microcapsules. If the mixing speed is too low, the aqueous mixture is agitated insufficiently and undesirably large microcapsules may be formed. Conversely, if the mixing speed is too high, high shear forces are generated and prevent shell material from forming on the microcapsules. Instead, gel particles form in the solution.
- the mixing speed is preferably between 100 and 1500 rpm, more preferably between 400 and 1000 rpm and even more preferably between 600 and 800 rpm. Particular mixing parameters depend on the type of equipment being used. Any of a variety of types of mixing equipment known in the art may be used. Particularly useful is an axial flow impeller, such as LightninTM A310 or A510.
- the aqueous mixture may then be cooled under controlled cooling rate and mixing parameters to permit coating of the primary microcapsules to form outer shells. It is advantageous to control the formation of the outer shell at a temperature above the gel point of the shell material. It is also possible at this stage to further add more polymer components, either of the same kind or a different kind, in order to thicken the outer shell and/or produce microcapsules having different layers of shells to provide desired functionalities.
- the temperature is preferably lowered at a rate of about 1° C./10 minutes until it reaches a temperature of from about 5° C. to about 10° C., preferably about 5° C.
- the outer shell encapsulates the primary microcapsules or clumps to form a rigid encapsulated agglomeration of microcapsules.
- a cross-linker may be added to further increase the rigidity of the microcapsules by cross-linking the shell material in both the outer and primary shells and to make the shells insoluble in both aqueous and non-aqueous (e.g., oil) media.
- Any suitable cross-linker may be used and the choice of cross-linker depends somewhat on the choice of shell material.
- Preferred cross-linkers are enzymatic cross-linkers (e.g. transglutaminase), aldehydes (e.g. formaldehyde or gluteraldehyde), tannic acid, alum, organic or inorganic calcium or potassium salt, or a mixture thereof.
- the cross-linkers are preferably non-toxic or of sufficiently low toxicity.
- the type and the amount of cross-linker used depend on the type of shell material and may be adjusted to provide more or less structural rigidity as desired.
- transglutaminase may be conveniently used in an amount of about 0.2% to about 2.0%, preferably about 1.0%, by weight of microcapsule suspension. In general, one skilled in the art may routinely determine the desired amount in any given case by simple experimentation.
- microcapsules have been produced. These microcapsules or other microcapsules may then be processed in accordance with the invention to add additional shell layers as described above.
- additional shells are added after the formation of the outer shell of the microcapsule or before the cross-linking step. More particularly, first and second polymer components of shell material are dissolved in aqueous solution e.g. at 40 to 60° C., more preferably around 50° C. pH may be controlled or adjusted at this stage. The microcapsules previously prepared are then combined with this mixture. Alternatively, the microcapsules may be combined with an aqueous solution of the first polymer component of shell material and then a second aqueous solution of the second polymer component of shell material may be added.
- pH, temperature, concentration, mixing speed or a combination thereof can then be adjusted as described above so that the polymer components of shell material form a complex coacervate surrounding and coating the microcapsules with an additional shell.
- processing aids may be incorporated as may be hydrophobic materials such as oils, waxes, resins or fats.
- the new outer shell may be then cross-linked as described above.
- the microcapsules may be washed with water and/or dried to provide a free-flowing powder. Drying may be accomplished by a number of methods known in the art, such as freeze drying, drying with ethanol or spray drying. Spray drying is a particularly preferred method for drying the microcapsules. Spray drying techniques are disclosed in “Spray Drying Handbook”, K. Masters, 5 th edition, Longman Scientific Technical UK, 1991, the disclosure of which is hereby incorporated by reference.
- the microcapsules produced by the processes of the present invention may be used to prepare liquids as free-flowing powders or compressed solids, to store a substance, to separate reactive substances, to reduce toxicity of a substance, to protect a substance against oxidation, to deliver a substance to a specified environment and/or to control the rate of release of a substance.
- the microcapsules may be used to deliver a biologically active substance to an organism for nutritional or medical purposes.
- the biologically active substance may be, for example, a nutritional supplement, a flavour, a drug and/or an enzyme.
- the organism is preferably a mammal, more preferably a human.
- Microcapsules containing the biologically active substance may be included, for example, in foods or beverages or in drug delivery systems. Use of the microcapsules of the present invention for formulating a nutritional supplement into human food is particularly preferred.
- Microcapsules of the present invention have good rupture strength to help reduce or prevent breaking of the microcapsules during incorporation into food or other formulations.
- the microcapsules' shells can be formulated to be insoluble in both aqueous and non-aqueous (e.g., oil) media, and help reduce or prevent oxidation and/or deterioration of the loading substance during preparation of the microcapsules, during long-term storage, and/or during incorporation of the microcapsules into a formulation vehicle, for example, into foods, beverages, nutraceutical formulations or pharmaceutical formulations.
- Multicore Microcapsules Prepared by One-Step Process for Comparison (both First and Second Shells having the Same Composition of Gelatine and Polyphosphate)
- gelatine 275 Bloom type A (isoelectric point of about 9) was mixed with 600 grams of deionized water containing 0.5% sodium ascorbate under agitation at 50° C. until completely dissolved. 5.45 grams of sodium polyphosphate was dissolved in 104 grams of deionized water containing 0.5% sodium ascorbate.
- the emulsion was diluted with 700 grams of deionized water containing 0.5% sodium ascorbate at 50° C.
- the sodium polyphosphate solution was then added into the emulsion and mixed with a LightninTM agitator at 600 rpm.
- the pH was then adjusted to 4.5 with a 10% aqueous acetic acid solution.
- a coacervate formed from the gelatine and polyphosphate coated onto the oil droplets to form primary microcapsules. Cooling was carried out to above the gel point of the gelatine and polyphosphate and the primary microcapsules started to agglomerate to form lumps under agitation.
- polymer remaining in the aqueous phase further coated the lumps of primary microcapsules to form an encapsulated agglomeration of microcapsules having an outer shell and having an average size of 50 ⁇ m.
- 2.7 grams of 50% gluteraldehyde was added into the mixture to further strengthen the shell.
- the mixture was then warmed to room temperature and kept stirring for 12 hours.
- the microcapsule suspension was washed with water. The washed suspension was then spray dried to obtain a free-flowing powder. A payload of 62% was obtained.
- Step A 15.6 grams gelatine 275 Bloom type A (isoelectric point of about 9) was mixed with 172 grams of deionized water containing 0.5% sodium ascorbate under agitation at 50° C. until completely dissolved. 1.56 grams of sodium polyphosphate was dissolved in 29.7 grams of deionized water containing 0.5% sodium ascorbate.
- the emulsion was diluted with 319 grams of deionized water containing 0.5% sodium ascorbate at 50° C.
- the sodium polyphosphate solution was then added into the emulsion and mixed with a LightninTM agitator at 600 rpm.
- the pH was then adjusted to 4.5 with a 10% aqueous phosphoric acid solution.
- a coacervate formed from the gelatine and polyphosphate coated onto the oil droplets to form primary microcapsules, and then the primary microcapsules started to agglomerate to form lumps under agitation.
- a payload of 80% was obtained at this step.
- Step B A gelatine solution was prepared by dissolving 41.8 grams of gelatine 275 Bloom type A (isoelectric point of about 9) in 460 grams of deionized water containing 0.5% sodium ascorbate under agitation at 50° C. until completely dissolved.
- a sodium polyphosphate solution was prepared by dissolving 4.18 grams of sodium polyphosphate in 79.5 grams of deionized water containing 0.5% sodium ascorbate. The gelatine and polyphosphate solutions were combined to form a mixture, and pH of the mixture was adjusted to 4.7 with 10% aqueous phosphoric acid.
- Step C The mixture from Step B was added to the mixture with lumps formed in step A. Cooling was carried out under agitation to cause the gelatine and polyphosphate to form coacervates and to coat the lumps formed in Step A to form an outer shell.
- the microcapsules thus formed had an average size of 60 ⁇ m. Once the temperature had been cooled to 5° C., 2.1 grams of 50% gluteraldehyde was added into the mixture to further strengthen the shell. The mixture was then warmed to room temperature and stirred continuously for 12 hours. Finally, the microcapsule suspension was washed with water. The washed suspension was then spray dried to obtain a free-flowing powder. A payload of 59% was obtained.
- Step A Same as Step A in Example 2.
- Step B A gelatine solution was prepared by dissolving 23.0 grams of gelatine 275 Bloom type A (isoelectric point of about 9) in 371 grams of deionized water under' agitation at 50° C. until completely dissolved.
- a sodium alginate (ISP Alginates) solution was prepared by dissolving 3.00 grams of sodium alginate in 503.8 grams of deionized water. The gelatine and sodium alginate solutions were combined to form a mixture. The pH of the mixture was adjusted to 5.00 with 10% aqueous phosphoric acid.
- Step C The mixture from Step B was added to the mixture with lumps formed in step A. Cooling was carried out under agitation to cause gelatine and alginate to form coacervates and coat the lumps formed in Step A to form an outer shell.
- the microcapsules thus formed had an average size of around 80 ⁇ m. Once the temperature had been cooled to 5° C., 2.1 grams of 50% gluteraldehyde was added into the mixture to further strengthen the shell. The mixture was then warmed to room temperature and stirred continuously for 12 hours. Finally, the microcapsule suspension was washed with water. The washed suspension was then spray dried to obtain a free-flowing powder. A payload of 53% was obtained.
- Step A 20.0 grams gelatine 275 Bloom type A (isoelectric point of about 9) was mixed with 220.1 grams of deionized water containing 0.5% sodium ascorbate under agitation at 50° C. until completely dissolved. 2.00 grams of sodium polyphosphate was dissolved in 38.0 grams of deionized water.
- the sodium polyphosphate solution was then added into the emulsion and mixed with a LightninTM agitator at 600 rpm.
- the pH was then adjusted to 4.5 with a 10% aqueous phosphoric acid solution.
- a coacervate formed from the gelatine and polyphosphate coated onto the oil droplets to form primary microcapsules, and then the primary microcapsules started to agglomerate to form lumps under agitation. A payload of 80% was obtained at this step.
- Step B A gelatine solution was prepared by dissolving 8.6 grams of gelatine 275 Bloom type A (isoelectric point of about 9) in 94.5 grams of deionized water under agitation at 65° C. until completely dissolved. 25.8 grams of beeswax melted at 65° C. was emulsified in the gelatine solution with a high speed PolytronTM homogenizer at 6,100 rpm for 4 minutes. A wax-in-water emulsion was formed. An alginate solution was prepared by dissolving 2.3 grams of sodium alginate in 192 grams of deionized water was added to the emulsion, and pH of the mixture was adjusted to 4.7 with 10% aqueous phosphoric acid.
- step A The mixture was then added into lump mixtures in step A under agitation at 800 rpm, and cooling was carried out to cause the gelatine-alginate-wax composite material to form a coating onto the lumps formed in Step A to form microcapsules.
- a payload of 60% was obtained at this step.
- Step C A solution was prepared by dissolving 23.1 grams of gelatine and 2.3 grams of sodium alginate in 384.9 grams of deionized water under agitation at 50° C. until completely dissolved. pH of the mixture was adjusted to 4.5 with 10% aqueous phosphoric acid, and the mixture was then added into microcapsule mixtures formed in step B under agitation at 800 rpm. Cooling was carried out to cause the gelatine-alginate material to form a coating onto the microcapsules that formed in Step B. Once the temperature had been cooled to 5° C., 1.5 grams of transglutaminase was added into the mixture to cross-link the shell. The mixture was then warmed to room temperature and kept stirring for 12 hours. Finally, the microcapsule suspension was spray dried to obtain a free-flowing powder. A final payload of 52% was obtained.
- Step A 13.0 grams of gelatine 275 Bloom type A (isoelectric point of about 9) was mixed with 143.0 grams of deionized water containing 0.5% sodium ascorbate under agitation at 50° C. until completely dissolved. 1.3 grams of sodium polyphosphate was dissolved in 24.7 grams of deionized water. 57.2 grams of fish oil containing 18% eicosapentaenoic acid (EPA) and 12% docosahexaenoic acid (DHA) (available from Ocean Nutrition Canada Ltd.) was dispersed with 1.0% of an antioxidant (mixed natural tocopherols) into the gelatine solution with a high speed PolytronTM homogenizer at 8,000 rpm for 4 minutes.
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- An oil-in-water emulsion was formed.
- the oil droplet size had a narrow distribution with an average size of about 1 ⁇ m measured by CoulterTM LS230 Particle Size Analyzer.
- the emulsion was diluted with 266.0 grams of deionized water at 50° C.
- the sodium polyphosphate solution was then added into the emulsion and mixed with a LightninTM agitator at 350 rpm.
- the pH was then adjusted to 4.4 with a 10% aqueous phosphoric acid solution.
- Step B A gelatine solution was prepared by dissolving 7.05 grams of gelatine 275 Bloom type A (isoelectric point of about 9) in 77.9 grams of deionized water under agitation at 70° C. until completely dissolved. 7.05 grams of beeswax melted at 70° C. was emulsified in the gelatine solution with a high speed PolytronTM homogenizer at 8,000 rpm for 4 minutes. A wax-in-water emulsion was formed. An alginate solution (45 ° C.) was prepared by dissolving 7.62 grams of sodium alginate in 630 grams of deionized water was added to the emulsion, and pH of the mixture was adjusted to 5.3 with 10% aqueous phosphoric acid.
- the mixture was then added into lump mixtures in step A under agitation at 450 rpm followed by adjusting the pH value of the mixture to 4.9, and cooling was carried out to cause the gelatine-alginate-wax composite material to form a coating onto the lumps formed in Step A to form microcapsules.
- the temperature had been lowered to 5° C.
- 3.8 grams of transglutaminase was added into the mixture to cross-link the shells.
- the mixture was then warmed up to room temperature and stirred at 600 rpm for 12 hours.
- the microcapsule suspension was spray dried to obtain a free-flowing powder. A final payload of 57% was obtained.
- FIG. 6 to FIG. 10 Images of microcapsules of Examples 1-5 are shown in FIG. 6 to FIG. 10 , respectively. It can be seen clearly that at approximately the same payload (60%) the microcapsules prepared with a two step process ( FIG. 7 ) have much thicker outer shells than those prepared with one step process ( FIG. 6 ). The microcapsules prepared with a three step process having a composite shell containing lipids ( FIG. 9 ) clearly show the lipid droplets incorporated in the second shell and near the agglomerated oil core.
- Accelerated oxidative stability in dry state was evaluated by placing the prepared microcapsule powders from each of Examples 1-4 in an oxygen bomb (OxipresTM, MIKROLAB AARHUS A/S, Denmark) with an initial oxygen pressure of 5 bar at a constant temperature of 65° C.
- OxipresTM MIKROLAB AARHUS A/S, Denmark
- an induction period or time was determined. A longer induction period means that the contents of the microcapsules are better protected towards oxidation.
- Induction periods are shown in Table 1.
- the microcapsules made from a two-step process in accordance with the invention have higher induction period (50-56 hours) than those made from a one-step process (41 hours). This translates to 22.0% to 37.6% increase in oxidative stability.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicinal Preparation (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
Single-core and multi-core microcapsules are provided, having multiple shells, at least one of which is formed of a complex coacervate of two components of shell materials. The complex coacervate may be the same or different for each shell. Also provided are methods for making the microcapsules.
Description
- This application claims the benefit of U.S. Provisional Patent Application No. 60/423,363 filed Nov. 4, 2002, which is incorporated by reference herein in its entirety.
- This invention relates to microcapsules having multiple shells, to methods of preparing microcapsules and to their use.
- Microcapsules are small particles of solids, or droplets of liquids, inside a thin coating of a shell material such as starch, gelatine, lipids, polysaccharides, wax or polyacrylic acids. They are used, for example, to prepare liquids as free-flowing powders or compressed solids, to separate reactive materials, to reduce toxicity, to protect against oxidation and/or to control the rate of release of a substance such as an enzyme, flavour, a nutrient, a drug, etc.
- Ideally, a microcapsule would have good mechanical strength (e.g. resistance to rupture) and the microcapsule shell would provide a good barrier to oxidation, etc.
- A typical approach to meeting these requirements is to increase the thickness of the microcapsule wall. But this results in an undesirable reduction in the loading capacity of the microcapsule. That is, the “payload” of the microcapsule, being the mass of the loading substance encapsulated in the microcapsule divided by the total mass of the microcapsule, is low. The typical payload of such “single-core” microcapsules made by spray drying an emulsion is in the range of about 25-50%.
- Another approach to the problem has been to create what are known as “multi-core” microcapsules. These microcapsules are usually formed by spray drying an emulsion of core material such that the shell material coats individual particles of core material, which then aggregate and form a cluster. A typical multi-core microcapsule is depicted in prior art
FIG. 1 .Multi-core microcapsule 10 contains a plurality ofcores 12. Thecores 12 take the form of entrapped particles of solids or of liquid droplets dispersed throughout a relatively continuous matrix ofshell material 14. As a result, there is a high ratio of shell material to loading material and the payload of the multi-core microcapsule is therefore low. Moreover, despite the high ratio of shell material to loading substance in such microcapsules, the shell material is poorly distributed. As shown in prior artFIG. 1 , many of thecores 12 are very close to thesurface 16 of the microcapsule. The cores at the surface are therefore not well protected against rupture or from oxidation. - Known microcapsules therefore either have a poor payload, or fail to adequately contain and protect the loading substance deposited therein. Moreover, because these microcapsules are generally prepared in a single step, it is difficult to incorporate multiple functionalities, such as oxidation resistance, moisture resistance and taste masking into a single microcapsule.
- In one aspect, the invention provides a multi-core microcapsule comprising: (a) an agglomeration of primary microcapsules, each primary microcapsule comprising a core and a first shell surrounding the core; (b) a second shell surrounding the agglomeration; and (c) a third shell surrounding the second shell; at least one of the first, second and third shells comprising a complex coacervate.
- In another aspect, the invention provides a single-core microcapsule comprising: (a) a core; (b) a first shell surrounding the core; and (c) a second shell surrounding the first shell; at least one of the first and second shells comprising a complex coacervate.
- In the case of either the multi-core or single-core microcapsules, it is preferred that all of the shells comprise a complex coacervate, which may be the same or different for each of the shells. Additional shells, e.g. from 1 to 20, may be added to further strengthen the microcapsule.
- In another aspect, the invention provides a process for making a microcapsule having a plurality of shells, the process comprising:
- (a) providing a microcapsule selected from the group consisting of:
- (i) a multi-core microcapsule comprising: an agglomeration of primary microcapsules, each primary microcapsule comprising a core and a first shell surrounding the core; and a second shell surrounding said agglomeration; and
- (ii) a single-core microcapsule comprising: a core; and a first shell surrounding the core;
- (b) mixing the microcapsule with first and second polymer components of shell material in aqueous solution;
- (c) adjusting at least one of pH, temperature, concentration and mixing speed to form shell material comprising the first and second polymer components, the shell material forming an additional shell enveloping the microcapsule;
wherein at least one of the first shell, the second shell and the additional shell comprises a complex coacervate. -
FIG. 1 depicts a typical prior art multi-core microcapsule. -
FIGS. 2 and 3 depict embodiments of the invention in which multi-core microcapsules are provided having multiple shells. -
FIGS. 4 and 5 depict embodiments of the invention in which single-core microcapsules are provided having multiple shells. -
FIG. 6 is a photomicrograph of multi-core microcapsules prepared with a one-step process (62% payload), prepared for purposes of comparison. -
FIG. 7 is a photomicrograph of multi-core microcapsules prepared with a two-step process in accordance with the invention (59% payload). -
FIG. 8 is a photomicrograph of multi-core microcapsules prepared with a two-step process in accordance with the invention in which alginate is incorporated in the outer shell (53% payload). -
FIG. 9 is a photomicrograph of multi-core microcapsules prepared with a three-step process in which lipids and alginate are incorporated in an inner shell while gelatine and polyphosphate forms an outer shell. -
FIG. 10 is a photomicrograph of multi-core microcapsules prepared with a two-step process in which lipids and alginate are incorporated in the second shell. - Any core material that may be encapsulated in microcapsules is useful in the invention. Indeed, in certain embodiments, commercially available microcapsules may be obtained and then further processed according to the processes of the invention.
- When the initial multi-core microcapsules are prepared according to processes as described herein involving an aqueous solution, the core material may be virtually any substance that is not entirely soluble in the aqueous solution. Preferably, the core is a solid, a hydrophobic liquid, or a mixture of a solid and a hydrophobic liquid. The core is more preferably a hydrophobic liquid, such as grease, oil or a mixture thereof. Typical oils may be fish oils, vegetable oils, mineral oils, derivatives thereof or mixtures thereof. The loading substance may comprise a purified or partially purified oily substance such as a fatty acid, a triglyceride or a mixture thereof. Omega-3 fatty acids, such as o-linolenic acid (18:3n3), octadecatetraenoic acid (18:4n3), eicosapentaenoic acid (20:5n3) (EPA) and docosahexaenoic acid (22:6n3) (DHA), and derivatives thereof and mixtures thereof, are preferred. Many types of derivatives are well known to one skilled in the art. Examples of suitable derivatives are esters, such as phytosterol esters, branched or unbranched C1-C30 alkyl esters, branched or unbranched C2-C30 alkenyl esters or branched or unbranched C3-C30 cycloalkyl esters, in particular phytosterol esters and C1-C6 alkyl esters. Preferred sources of oils are oils derived from aquatic organisms (e.g. anchovies, capelin, Atlantic cod, Atlantic herring, Atlantic mackerel, Atlantic menhaden, salmonids, sardines, shark, tuna, etc) and plants (e.g. flax, vegetables, algae, etc).
- While the core may or may not be a biologically active substance such as a tocopherol, antioxidant or vitamin, the microcapsules of the present invention are particularly suited for biologically active substances, for example, drugs, nutritional supplements, flavours, antioxidants or mixtures thereof.
- Coacervation is a phase separation phenomenon, in which a homogenous polymer solution is converted into two phases. One is a polymer-rich phase, called a coacervate. The other is a polymer-poor phase, i.e., solvent. Complex coacervation is caused by the interaction of two oppositely charged polymers.
- Preferably, a positively charged polymer component “A” interacts with a negatively charged polymer component “B”. For example, positively charged type A gelatine (“component A”) forms complex coacervates with negatively charged polyphosphate (“component B”). Other systems that have been studied are gelatine/gum Acacia, gelatine/pectin, gelatine/carboxymethyl guar gum and whey protein/gum arabic.
- Component A is preferably gelatine type A, chitosan, etc., although other polymers are also contemplated as component A. Component B is preferably gelatine type B, polyphosphate, gum arabic, alginate, carrageenan, pectin, carboxymethylcellulose, or a mixture thereof.
- In addition to the charge density of the two polymer components, complex coacervation depends on other factors such as molecular weight of the polymers and their ratio, ionic strength, pH and temperature of the medium (J. Microencapsulation, 2003, Vol. 20, No. 2: 203-210).
- The molar ratio of component A:component B that is used depends on the type of components but is typically from 1:5 to 15:1. For example, when gelatine type A and polyphosphate are used as components A and B respectively, the molar ratio of component A:component B is preferably 8:1 to 12:1; when gelatine type A and gelatine type B are used as components A and B respectively, the molar ratio of component A:component B is preferably 2:1 to 1:2; and when gelatine type A and alginate are used as components A and B respectively, the molar ratio of component A:component B is preferably 3:1 to 5:1.
- One suitable process of microencapsulation using complex coacervation comprises three steps: 1) dispersing the loading substance into a system of at least one of the polymers for the complex coacervate; 2) forming shells by deposition of coacervates which derive from the polymeric components under controlled conditions of temperature, pH, concentration of colloids, mixing speed etc.; and 3) hardening of the shells by crosslinking of the coacervates deposited on microcapsules (Ullmann's Encyclopedia of Industrial Chemistry 6th edition. 2001, Vol. A16. pp. 575-588).
- Any shells that do not comprise complex coacervates may be formed of any material that can form an additional shell around the microcapsule. The additional shell material typically comprises at least one polymer component. Examples of polymer components include, but are not limited to, proteins, e.g. gelatines, soy proteins, whey proteins, and milk proteins, polyphosphate, polysaccharides and mixtures thereof. Preferred polymer components are gelatine A, gelatine B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin, cellulose or derivatives of cellulose such as carboxymethylcellulose (CMC) or a mixture thereof. A particularly preferred form of gelatine type A has a Bloom strength of 50-350, more preferably a Bloom strength of about 275.
- The shell material can also comprise lipids, such as waxes, fatty acids and oils, etc. to provide desired functionalities. The incorporation of lipids into the shell material improves the impermeability of the shell to water and oxygen. A preferred lipid for this purpose is beeswax. These lipids may be in solid, semi-solid or liquid form.
- Processing aids may be included in the shell material. Processing aids may be used for a variety of reasons. For example, they may be used to promote agglomeration of primary microcapsules when forming multi-core microcapsules, control microcapsule size and shape and/or to act as an antioxidant. Antioxidant properties are useful both during the process (e.g. during coacervation and/or spray drying) and in the microcapsules after they are formed (e.g. to extend shelf-life of loading substances which are readily oxidized, etc). Preferably a small number of processing aids that perform a large number of functions are used. For example, ascorbic acid or a salt thereof may be used to promote agglomeration of the primary microcapsules, to control microcapsule size and shape and to act as an antioxidant. The ascorbic acid or salt thereof is preferably used in an amount of about 100 ppm to about 10,000 ppm, more preferably about 1000 ppm to about 5000 ppm relative to the batch size (i.e., the total weight). A salt of ascorbic acid, such as sodium or potassium ascorbate, is particularly preferred in this capacity. Other processing aids include, without limitation, buffering acids and/or their salts such as phosphoric acid, acetic acid, citric acid, and the like.
- In one embodiment, microcapsules of the invention have a structure generally as depicted in
FIG. 2 .FIG. 2 depicts a multi-core microcapsule prepared according to a multi-step process of the invention. Primary microcapsules comprise cores 18 (i.e. the loading substance) surrounded byfirst shells 20. The primary microcapsules agglomerate and thespace 22 between them is usually at least partly filled by additional shell material of same composition asfirst shell 20, although there may be voids between some of the primary microcapsules. The agglomeration of primary microcapsules is surrounded by asecond shell 24. - Multi-core microcapsules comprising
second shell 24 may be prepared according to the processes described herein and exemplified in the examples or by generally the same techniques that are described in Applicant's co-pending U.S. patent application Ser. No. 10/120,621 filed Apr. 11, 2002, corresponding to International Application No. PCT/CA2003/000520 filed Apr. 8, 2003, the disclosures of both of which are incorporated herein by reference. These multi-core microcapsules are particularly useful because the foam-like structure of primary microcapsules, supported by additional shell material inspace 22 and surrounded bysecond shell 24 is an extremely strong, rupture-resistant structure that has a high payload i.e. the ratio of the total mass of the cores to the total mass of the multi-core microcapsule is very high, e.g. at least 50, 55, 60, 65, 70, 75, 80, 85, 90% or higher. This is called a “one-step” process whenshells shells - Commercially available multicore microcapsules may also be used as starting materials. An example is the Driphorm™ Hi-DHA™ microencapsulated tuna oil, manufactured by Nu-Mega Ingredients Pty. Ltd., Queensland, AU.
- In accordance with the invention, a three-step process takes place when a
third shell 26 is formed on the multi-core microcapsule.Third shell 26 further strengthens the microcapsule and can be advantageously used to provide a shell having properties different from those ofshell 24. - For instance, different polymer components can be incorporated into
third shell 26. In addition, or alternatively, lipids may be incorporated intoshell 26 to increase moisture or oxygen impermeability or the like. These properties might instead be incorporated intosecond shell 24 rather than third shell 26 (or also intosecond shell 24 as well as into third shell 26), depending on the requirements for a particular purpose. Additional shells, not shown inFIG. 2 , may be formed aroundthird shell 26, by the methods and techniques of the invention. For instance, N additional shells could be added, wherein N is an integer from 1 to 20. - At least one of
shells shell 20; (b)shell 24; (c)shell 26; (d)shells shells shells shells - Referring again to
FIG. 2 , the primary microcapsules (i.e.cores 18 surrounded by first shells 20) typically have an average diameter of about 40 nm to about 10 μm, more particularly from about 0.1 μm to about 5 μm, even more particularly an average diameter of about 1-2 μm. The finished multi-core microcapsule, i.e. includingthird shell 26, usually has an average diameter from about 1 μm to about 2000 μm, more typically from about 20 μm to about 1000 μm, more particularly from about 20 μm to about 100 μm and even more particularly from about 50 μm to about 100 μm. - In
FIG. 2 ,second shell 24 andthird shell 26 are depicted as discrete layers. This will be the case if the shells are formed of the different shell materials. In that case, even if they do not differ in appearance, they will have a different composition and can be represented as discrete, distinct layers. But ifsecond shell 24 andthird shell 26 are formed of the same shell material, they may, as shown inFIG. 3 , merge to form a single, continuous layer, having the combined thickness ofsecond shell 24 andthird shell 26. As shown inFIG. 3 , when the second and third shells are of the same composition, there may be no discrete boundary separating them. This would be true also in microcapsules of the invention having fourth or additional shells that are of the same composition as the preceding shell. - The invention is also useful in the preparation of single-core microcapsules having multiple shells. Single-core microcapsules useful as starting materials are commercially available. Examples include microencapsulated flavours by Givaudan Flavors Corp., Cincinnati, Ohio, USA, and microencapsulated minerals and vitamins by Watson Food Co. Inc., West Haven, Conn., USA. Alternatively, they can be made by complex coacervation processes as described herein, e.g. by preparing primary microcapsules without a further agglomeration step.
FIG. 4 depicts a single-core microcapsule having multiple shells in accordance with the invention.Core 18 is surrounded by afirst shell 20 and asecond shell 24. Additional shells, not shown inFIG. 4 , may be formed aroundsecond shell 24, by the methods and techniques of the invention. For instance, N additional shells could be added, wherein N is an integer from 1 to 20. - As with the multi-core microcapsules,
shells shells shell 20; (b)shell 24; or (c)shells - Single-core microcapsules may be as large as multi-core microcapsules. For instance, the exterior diameter of
second shell 24 in the single-core microcapsule ofFIG. 4 may be from about 1 μm to about 2000 μm. More typically it will be from about 20 μm to about 1000 μm, more particularly from about 20 μm to about 100 μm and even more particularly from about 50 μm to about 100 μm. - When they are of the same composition,
first shell 20 and second shell 24 (and any additional shell) of the single-core multicapsule may merge to form a single continuous layer as depicted inFIG. 5 . This may be done in a one-step process. - Single or multi-core microcapsules to which additional shells may be added by the processes of the invention may be obtained from commercial sources. In a particularly preferred embodiment, multi-core microcapsules prepared in accordance with applicant's co-pending U.S. patent application Ser. No. 10/120,621 filed Apr. 11, 2002, corresponding to International Application No. PCT/CA2003/000520 filed Apr. 8, 2003, the disclosures of both of which are incorporated herein by reference, are used. Such microcapsules can be prepared e.g. by a one step process as follows.
- An aqueous mixture of a loading substance (i.e.
- core material) and a polymer component of the shell material is formed. The aqueous mixture may be a mechanical mixture, a suspension or an emulsion. When a liquid loading material is used, particularly a hydrophobic liquid, the aqueous mixture is preferably an emulsion of the loading material and the polymer components.
- In a more preferred aspect, a first polymer component is provided in aqueous solution, preferably together with processing aids, such as antioxidants. A loading substance may then be dispersed into the aqueous mixture, for example, by using a homogenizer. If the loading substance is a hydrophobic liquid, an emulsion is formed in which a fraction of the first polymer component begins to deposit around individual droplets of loading substance to begin the formation of primary shells. If the loading substance is a solid particle, a suspension is formed in which a fraction of the first polymer component begins to deposit around individual particles to begin the formation of primary shells. At this point, another aqueous solution of a second polymer component may be added to the aqueous mixture.
- Droplets or particles of the loading substance in the aqueous mixture preferably have an average diameter of less than 100 μm, more preferably less than 50 μm, even more preferably less than 25 μm. Droplets or particles of the loading substance having an average diameter less than 10 μm or less than 5 μm or less than 3 μm or less than 1 μm may be used. Particle size may be measured using any typical equipment known in the art, for example, a Coulter™ LS230 Particle Size Analyzer, Miami, Fla., USA.
- The amount of the polymer components of the shell material provided in the aqueous mixture is typically sufficient to form both the primary and outer shells of microcapsules. Preferably, the loading substance is provided in an amount of from about 1% to about 15% by weight of the aqueous mixture, more preferably from about 3% to about 8% by weight, and even more preferably about 6% by weight.
- If a complex coacervate is desired, the pH, temperature, concentration, mixing speed or a combination thereof is then adjusted to accelerate the formation of the primary shells of complex coacervate around the droplets or particles of the loading substance to form primary microcapsules. In the case of multicore microcapsules, agglomeration of the primary microcapsules will take place to form discrete clumps at desired size and shape.
- pH is an expression of the concentration of hydrogen ions in solution. Such ions affect the ionization equilibria of the component A and B polymers involved in complex coacervation and thus the formation of complex coacervates. The pH is adjusted so that the component A polymer will bear a net positive charge and the component B polymer will bear a net negative charge. Hence, the pH adjustment depends on the type of shell material to be used.
- For example, when gelatine type A is a polymer component, the gelatine molecules have nearly equal positive and negative charges (i.e. zero net polarity change) at their point of zero charge (pzc) around pH 9-10. Only when the solution pH is lower than the pzc value, will the polymer bear a net positive charge, which interacts with the negatively charged component B (e.g. gum arabic, polyphosphate, alginate, etc.).
- In the case of gelatine type A, the pH is preferably adjusted to a value from 3.5-5.0, more preferably from 4.0-5.0. Much outside this range, the gelatine-based complex tends to form gels upon cooling rather than a shell on the microcapsules. If the pH of the mixture starts in the desired range, then little or no pH adjustment is required.
- The molar ratio of components A and B is adjusted to favour formation of shells on the microcapsules rather than merely the formation of gel particles in solution. Suitable molar ratios are discussed above under the heading “Shell Material”.
- The concentration of components A and B in the aqueous mixture may also affect the formation of complex coacervates and can be adjusted accordingly. Typically, the total concentration of components A and B varies from 1% to 20%, preferably 2-10%, and more preferably 3-6% by weight of the aqueous mixture. For instance, when gelatine type A is used as component A, the concentration of gelatine type A is preferably from 1-15% by weight of the aqueous mixture, more preferably 2-6% by weight and even more preferably 2-4% by weight. Similarly, when polyphosphate is used as component B, its concentration in the aqueous mixture is preferably 0.01-0.65% by weight of the aqueous mixture, more preferably 0.13-0.17% by weight, even more preferably 0.13-0.26% by weight.
- The initial temperature of the aqueous mixture is preferably set to a value of from about 40° C. to about 60° C., more preferably at about 50° C.
- Mixing speed influences the deposition of complex coacervates on the surface of microcapsules. If the mixing speed is too low, the aqueous mixture is agitated insufficiently and undesirably large microcapsules may be formed. Conversely, if the mixing speed is too high, high shear forces are generated and prevent shell material from forming on the microcapsules. Instead, gel particles form in the solution. The mixing speed is preferably between 100 and 1500 rpm, more preferably between 400 and 1000 rpm and even more preferably between 600 and 800 rpm. Particular mixing parameters depend on the type of equipment being used. Any of a variety of types of mixing equipment known in the art may be used. Particularly useful is an axial flow impeller, such as Lightnin™ A310 or A510.
- At this time, materials for outer shell are added into the mixture, and the aqueous mixture may then be cooled under controlled cooling rate and mixing parameters to permit coating of the primary microcapsules to form outer shells. It is advantageous to control the formation of the outer shell at a temperature above the gel point of the shell material. It is also possible at this stage to further add more polymer components, either of the same kind or a different kind, in order to thicken the outer shell and/or produce microcapsules having different layers of shells to provide desired functionalities. The temperature is preferably lowered at a rate of about 1° C./10 minutes until it reaches a temperature of from about 5° C. to about 10° C., preferably about 5° C. The outer shell encapsulates the primary microcapsules or clumps to form a rigid encapsulated agglomeration of microcapsules.
- At this stage, a cross-linker may be added to further increase the rigidity of the microcapsules by cross-linking the shell material in both the outer and primary shells and to make the shells insoluble in both aqueous and non-aqueous (e.g., oil) media. Any suitable cross-linker may be used and the choice of cross-linker depends somewhat on the choice of shell material. Preferred cross-linkers are enzymatic cross-linkers (e.g. transglutaminase), aldehydes (e.g. formaldehyde or gluteraldehyde), tannic acid, alum, organic or inorganic calcium or potassium salt, or a mixture thereof. When the microcapsules are to be used to deliver a biologically active substance to an organism, the cross-linkers are preferably non-toxic or of sufficiently low toxicity. The type and the amount of cross-linker used depend on the type of shell material and may be adjusted to provide more or less structural rigidity as desired. For example, when gelatine type A is used in the shell material, transglutaminase may be conveniently used in an amount of about 0.2% to about 2.0%, preferably about 1.0%, by weight of microcapsule suspension. In general, one skilled in the art may routinely determine the desired amount in any given case by simple experimentation.
- At this stage, multi-core microcapsules have been produced. These microcapsules or other microcapsules may then be processed in accordance with the invention to add additional shell layers as described above. Preferably, additional shells are added after the formation of the outer shell of the microcapsule or before the cross-linking step. More particularly, first and second polymer components of shell material are dissolved in aqueous solution e.g. at 40 to 60° C., more preferably around 50° C. pH may be controlled or adjusted at this stage. The microcapsules previously prepared are then combined with this mixture. Alternatively, the microcapsules may be combined with an aqueous solution of the first polymer component of shell material and then a second aqueous solution of the second polymer component of shell material may be added. pH, temperature, concentration, mixing speed or a combination thereof can then be adjusted as described above so that the polymer components of shell material form a complex coacervate surrounding and coating the microcapsules with an additional shell. As discussed above, processing aids may be incorporated as may be hydrophobic materials such as oils, waxes, resins or fats. The new outer shell may be then cross-linked as described above. These additional steps of forming additional shell layers may be repeated as desired to build up a suitable number of further shells on the microcapsule.
- Finally, the microcapsules may be washed with water and/or dried to provide a free-flowing powder. Drying may be accomplished by a number of methods known in the art, such as freeze drying, drying with ethanol or spray drying. Spray drying is a particularly preferred method for drying the microcapsules. Spray drying techniques are disclosed in “Spray Drying Handbook”, K. Masters, 5th edition, Longman Scientific Technical UK, 1991, the disclosure of which is hereby incorporated by reference.
- The microcapsules produced by the processes of the present invention may be used to prepare liquids as free-flowing powders or compressed solids, to store a substance, to separate reactive substances, to reduce toxicity of a substance, to protect a substance against oxidation, to deliver a substance to a specified environment and/or to control the rate of release of a substance. In particular, the microcapsules may be used to deliver a biologically active substance to an organism for nutritional or medical purposes. The biologically active substance may be, for example, a nutritional supplement, a flavour, a drug and/or an enzyme. The organism is preferably a mammal, more preferably a human. Microcapsules containing the biologically active substance may be included, for example, in foods or beverages or in drug delivery systems. Use of the microcapsules of the present invention for formulating a nutritional supplement into human food is particularly preferred.
- Microcapsules of the present invention have good rupture strength to help reduce or prevent breaking of the microcapsules during incorporation into food or other formulations. Furthermore, the microcapsules' shells can be formulated to be insoluble in both aqueous and non-aqueous (e.g., oil) media, and help reduce or prevent oxidation and/or deterioration of the loading substance during preparation of the microcapsules, during long-term storage, and/or during incorporation of the microcapsules into a formulation vehicle, for example, into foods, beverages, nutraceutical formulations or pharmaceutical formulations.
- The invention will now be further illustrated by the following non-limiting examples.
- 54.5 grams gelatine 275 Bloom type A (isoelectric point of about 9) was mixed with 600 grams of deionized water containing 0.5% sodium ascorbate under agitation at 50° C. until completely dissolved. 5.45 grams of sodium polyphosphate was dissolved in 104 grams of deionized water containing 0.5% sodium ascorbate. 90 grams of a fish oil concentrate containing 30% eicosapentaenoic acid ethyl ester (EPA) and 20% docosahexaenoic acid ethyl ester (DHA) (available from Ocean Nutrition Canada Ltd.) was dispersed with 1.0% of an antioxidant (mixed natural tocopherols) into the gelatine solution with a high speed Polytron™ homogenizer at 5,500 rpm for 6 minutes. An oil-in-water emulsion was formed. The oil droplet size had a narrow distribution with an average size of about 1 μm measured by Coulter™ LS230 Particle Size Analyzer. The emulsion was diluted with 700 grams of deionized water containing 0.5% sodium ascorbate at 50° C. The sodium polyphosphate solution was then added into the emulsion and mixed with a Lightnin™ agitator at 600 rpm. The pH was then adjusted to 4.5 with a 10% aqueous acetic acid solution. During pH adjustment and the cooling step that followed pH adjustment, a coacervate formed from the gelatine and polyphosphate coated onto the oil droplets to form primary microcapsules. Cooling was carried out to above the gel point of the gelatine and polyphosphate and the primary microcapsules started to agglomerate to form lumps under agitation. Upon further cooling of the mixture, polymer remaining in the aqueous phase further coated the lumps of primary microcapsules to form an encapsulated agglomeration of microcapsules having an outer shell and having an average size of 50 μm. Once the temperature had been cooled to 5° C., 2.7 grams of 50% gluteraldehyde was added into the mixture to further strengthen the shell. The mixture was then warmed to room temperature and kept stirring for 12 hours. Finally, the microcapsule suspension was washed with water. The washed suspension was then spray dried to obtain a free-flowing powder. A payload of 62% was obtained.
- A Two-Step Process with Gelatine and Polyphosphate in both First and Second Shells, but having Different Compositions
- Step A: 15.6 grams gelatine 275 Bloom type A (isoelectric point of about 9) was mixed with 172 grams of deionized water containing 0.5% sodium ascorbate under agitation at 50° C. until completely dissolved. 1.56 grams of sodium polyphosphate was dissolved in 29.7 grams of deionized water containing 0.5% sodium ascorbate. 69 grams of a fish oil concentrate containing 30% eicosapentaenoic acid ethyl ester (EPA) and 20% docosahexaenoic acid ethyl ester (DHA) (available from Ocean Nutrition Canada Ltd.) was dispersed with 1.0% of an antioxidant (mixed natural tocopherols) into the gelatine solution with a high speed Polytron™ homogenizer at 6,100 rpm for 4 minutes. An oil-in-water emulsion was formed. The oil droplet size had a narrow distribution with an average size of about 1 μm measured by Coulter™ LS230 Particle Size Analyzer. The emulsion was diluted with 319 grams of deionized water containing 0.5% sodium ascorbate at 50° C. The sodium polyphosphate solution was then added into the emulsion and mixed with a Lightnin™ agitator at 600 rpm. The pH was then adjusted to 4.5 with a 10% aqueous phosphoric acid solution. During pH adjustment and the cooling step that followed pH adjustment, a coacervate formed from the gelatine and polyphosphate coated onto the oil droplets to form primary microcapsules, and then the primary microcapsules started to agglomerate to form lumps under agitation. A payload of 80% was obtained at this step.
- Step B: A gelatine solution was prepared by dissolving 41.8 grams of gelatine 275 Bloom type A (isoelectric point of about 9) in 460 grams of deionized water containing 0.5% sodium ascorbate under agitation at 50° C. until completely dissolved. A sodium polyphosphate solution was prepared by dissolving 4.18 grams of sodium polyphosphate in 79.5 grams of deionized water containing 0.5% sodium ascorbate. The gelatine and polyphosphate solutions were combined to form a mixture, and pH of the mixture was adjusted to 4.7 with 10% aqueous phosphoric acid.
- Step C: The mixture from Step B was added to the mixture with lumps formed in step A. Cooling was carried out under agitation to cause the gelatine and polyphosphate to form coacervates and to coat the lumps formed in Step A to form an outer shell. The microcapsules thus formed had an average size of 60 μm. Once the temperature had been cooled to 5° C., 2.1 grams of 50% gluteraldehyde was added into the mixture to further strengthen the shell. The mixture was then warmed to room temperature and stirred continuously for 12 hours. Finally, the microcapsule suspension was washed with water. The washed suspension was then spray dried to obtain a free-flowing powder. A payload of 59% was obtained.
- Step A: Same as Step A in Example 2.
- Step B: A gelatine solution was prepared by dissolving 23.0 grams of gelatine 275 Bloom type A (isoelectric point of about 9) in 371 grams of deionized water under' agitation at 50° C. until completely dissolved. A sodium alginate (ISP Alginates) solution was prepared by dissolving 3.00 grams of sodium alginate in 503.8 grams of deionized water. The gelatine and sodium alginate solutions were combined to form a mixture. The pH of the mixture was adjusted to 5.00 with 10% aqueous phosphoric acid.
- Step C: The mixture from Step B was added to the mixture with lumps formed in step A. Cooling was carried out under agitation to cause gelatine and alginate to form coacervates and coat the lumps formed in Step A to form an outer shell. The microcapsules thus formed had an average size of around 80 μm. Once the temperature had been cooled to 5° C., 2.1 grams of 50% gluteraldehyde was added into the mixture to further strengthen the shell. The mixture was then warmed to room temperature and stirred continuously for 12 hours. Finally, the microcapsule suspension was washed with water. The washed suspension was then spray dried to obtain a free-flowing powder. A payload of 53% was obtained.
- Step A: 20.0 grams gelatine 275 Bloom type A (isoelectric point of about 9) was mixed with 220.1 grams of deionized water containing 0.5% sodium ascorbate under agitation at 50° C. until completely dissolved. 2.00 grams of sodium polyphosphate was dissolved in 38.0 grams of deionized water. 88.0 grams of a fish oil concentrate containing 30% eicosapentaenoic acid ethyl ester (EPA) and 20% docosahexaenoic acid ethyl ester (DHA) (available from Ocean Nutrition Canada Ltd.) was dispersed with 1.0% of an antioxidant (mixed natural tocopherols) into the gelatine solution with a high speed Polytron™ homogenizer at 6,100 rpm for 4 minutes. An oil-in-water emulsion was formed. The oil droplet size had a narrow distribution with an average size of about 1 μm measured by Coulter™ LS230 Particle Size Analyzer. The emulsion was diluted with 408.6 grams of deionized water at 50° C. The sodium polyphosphate solution was then added into the emulsion and mixed with a Lightnin™ agitator at 600 rpm. The pH was then adjusted to 4.5 with a 10% aqueous phosphoric acid solution. During pH adjustment and the cooling step that followed pH adjustment, a coacervate formed from the gelatine and polyphosphate coated onto the oil droplets to form primary microcapsules, and then the primary microcapsules started to agglomerate to form lumps under agitation. A payload of 80% was obtained at this step.
- Step B: A gelatine solution was prepared by dissolving 8.6 grams of gelatine 275 Bloom type A (isoelectric point of about 9) in 94.5 grams of deionized water under agitation at 65° C. until completely dissolved. 25.8 grams of beeswax melted at 65° C. was emulsified in the gelatine solution with a high speed Polytron™ homogenizer at 6,100 rpm for 4 minutes. A wax-in-water emulsion was formed. An alginate solution was prepared by dissolving 2.3 grams of sodium alginate in 192 grams of deionized water was added to the emulsion, and pH of the mixture was adjusted to 4.7 with 10% aqueous phosphoric acid. The mixture was then added into lump mixtures in step A under agitation at 800 rpm, and cooling was carried out to cause the gelatine-alginate-wax composite material to form a coating onto the lumps formed in Step A to form microcapsules. A payload of 60% was obtained at this step.
- Step C: A solution was prepared by dissolving 23.1 grams of gelatine and 2.3 grams of sodium alginate in 384.9 grams of deionized water under agitation at 50° C. until completely dissolved. pH of the mixture was adjusted to 4.5 with 10% aqueous phosphoric acid, and the mixture was then added into microcapsule mixtures formed in step B under agitation at 800 rpm. Cooling was carried out to cause the gelatine-alginate material to form a coating onto the microcapsules that formed in Step B. Once the temperature had been cooled to 5° C., 1.5 grams of transglutaminase was added into the mixture to cross-link the shell. The mixture was then warmed to room temperature and kept stirring for 12 hours. Finally, the microcapsule suspension was spray dried to obtain a free-flowing powder. A final payload of 52% was obtained.
- Step A: 13.0 grams of gelatine 275 Bloom type A (isoelectric point of about 9) was mixed with 143.0 grams of deionized water containing 0.5% sodium ascorbate under agitation at 50° C. until completely dissolved. 1.3 grams of sodium polyphosphate was dissolved in 24.7 grams of deionized water. 57.2 grams of fish oil containing 18% eicosapentaenoic acid (EPA) and 12% docosahexaenoic acid (DHA) (available from Ocean Nutrition Canada Ltd.) was dispersed with 1.0% of an antioxidant (mixed natural tocopherols) into the gelatine solution with a high speed Polytron™ homogenizer at 8,000 rpm for 4 minutes. An oil-in-water emulsion was formed. The oil droplet size had a narrow distribution with an average size of about 1 μm measured by Coulter™ LS230 Particle Size Analyzer. The emulsion was diluted with 266.0 grams of deionized water at 50° C. The sodium polyphosphate solution was then added into the emulsion and mixed with a Lightnin™ agitator at 350 rpm. The pH was then adjusted to 4.4 with a 10% aqueous phosphoric acid solution. During pH adjustment and the cooling step that followed pH adjustment, a coacervate formed from the gelatine and polyphosphate coated onto the oil droplets to form primary microcapsules, and then the primary microcapsules started to agglomerate to form lumps under agitation. A payload of 80% was obtained at this step.
- Step B: A gelatine solution was prepared by dissolving 7.05 grams of gelatine 275 Bloom type A (isoelectric point of about 9) in 77.9 grams of deionized water under agitation at 70° C. until completely dissolved. 7.05 grams of beeswax melted at 70° C. was emulsified in the gelatine solution with a high speed Polytron™ homogenizer at 8,000 rpm for 4 minutes. A wax-in-water emulsion was formed. An alginate solution (45 ° C.) was prepared by dissolving 7.62 grams of sodium alginate in 630 grams of deionized water was added to the emulsion, and pH of the mixture was adjusted to 5.3 with 10% aqueous phosphoric acid. The mixture was then added into lump mixtures in step A under agitation at 450 rpm followed by adjusting the pH value of the mixture to 4.9, and cooling was carried out to cause the gelatine-alginate-wax composite material to form a coating onto the lumps formed in Step A to form microcapsules. Once the temperature had been lowered to 5° C., 3.8 grams of transglutaminase was added into the mixture to cross-link the shells. The mixture was then warmed up to room temperature and stirred at 600 rpm for 12 hours. Finally, the microcapsule suspension was spray dried to obtain a free-flowing powder. A final payload of 57% was obtained.
- Images of microcapsules of Examples 1-5 are shown in
FIG. 6 toFIG. 10 , respectively. It can be seen clearly that at approximately the same payload (60%) the microcapsules prepared with a two step process (FIG. 7 ) have much thicker outer shells than those prepared with one step process (FIG. 6 ). The microcapsules prepared with a three step process having a composite shell containing lipids (FIG. 9 ) clearly show the lipid droplets incorporated in the second shell and near the agglomerated oil core. - Accelerated oxidative stability in dry state was evaluated by placing the prepared microcapsule powders from each of Examples 1-4 in an oxygen bomb (Oxipres™, MIKROLAB AARHUS A/S, Denmark) with an initial oxygen pressure of 5 bar at a constant temperature of 65° C. When the encapsulated fish oil started to oxidize, the oxygen pressure dropped, and an induction period or time was determined. A longer induction period means that the contents of the microcapsules are better protected towards oxidation.
- Induction periods are shown in Table 1. The microcapsules made from a two-step process in accordance with the invention have higher induction period (50-56 hours) than those made from a one-step process (41 hours). This translates to 22.0% to 37.6% increase in oxidative stability.
-
TABLE I Comparison of the microcapsules described in Examples 1-5. Induction Loading period Example # Figure # Description (%) (hr) 1 6 Multicore one-step 62 41 process for comparison 2 7 Two-step process 59 50 with gelatine and polyphosphate in outer shell 3 8 Two-step process 53 55 with alginate in outer shell 4 9 Three-step process 52 44 incorporating wax and alginate in the second shell and gelatine and polyphosphate in the third shell 5 10 Two-step process 57 56 incorporating wax and alginate in the shell - All publications cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference. The citation of any publication should not be construed as an admission that such publication is prior art.
- Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this specification that certain changes or modifications may be made thereto without departing from the spirit or scope of the appended claims.
Claims (16)
1. A multi-core microcapsule comprising: (a) an agglomeration of primary microcapsules, each primary microcapsule comprising a core and a first shell surrounding said core; (b) a second shell surrounding said agglomeration; and (c) a third shell surrounding said second shell; at least one of said first, second and third shells comprising a complex coacervate.
2. The multi-core microcapsule according to claim 1 , wherein each of said first, second and third shells comprises a complex coacervate.
3. The multi-core microcapsule according to claim 1 , wherein each of said first, second and third shells comprises the same complex coacervate.
4. The multi-core microcapsule according to claim 1 , wherein at least one of said first, second and third shells comprises a complex coacervate that is different than a complex coacervate that forms one of the other shells.
5. The multi-core microcapsule according to claim 1 , wherein said complex coacervate comprises at least one polymer component selected from the group consisting of: a protein, a polyphosphate, a polysaccharide, gum arabic, alginate, chitosan, carrageenan, pectin, cellulose and cellulose derivatives.
6. The multi-core microcapsule according to claim 5 , wherein said protein is selected from the group consisting of gelatine type A, gelatine type B, soy proteins, whey proteins, milk proteins, and combinations thereof.
7. The multi-core microcapsule according to claim 1 , wherein at least one of said first, second and third shells comprises a complex coacervate between gelatine A and at least one polymer component selected from the group consisting of gelatine type B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin and carboxymethylcellulose.
8. The multi-core microcapsule according to claim 1 , wherein at least one of said first, second and third shells is a complex coacervate between gelatine A and polyphosphate.
9. The multi-core microcapsule according to claim 1 , further comprising at least one additional shell surrounding said third shell.
10. The multi-core microcapsule according to claim 9 , wherein said at least one additional shell surrounding said third shell comprises a complex coacervate.
11. The multi-core microcapsule according to claim 1 , wherein at least one of said first second and third shells comprises an antioxidant.
12. The multi-core microcapsule according to claim 1 , wherein at least one of said first, second and third shells comprises one or more hydrophobic components selected from the group consisting of waxes, oils, resins, and fats.
13. The multi-core microcapsule according to claim 1 , wherein at least one of said first, second and third shells comprises a complex coacervate that is cross-linked with a cross-linker.
14. The multi-core microcapsule according to claim 1 , wherein said cores comprise at least 50% of the total mass of the multi-core microcapsule.
15. The multi-core microcapsule according to claim 1 , having an exterior average diameter of from about 1 μm to about 2000 μm, and wherein said first shells have an average diameter of from about 40 nm to about 10 μm.
16-45. (canceled)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/642,303 US20100092571A1 (en) | 2002-11-04 | 2009-12-18 | Microcapsules having multiple shells and method for the preparation thereof |
US13/009,418 US8900630B2 (en) | 2002-11-04 | 2011-01-19 | Microcapsules having multiple shells and method for the preparation thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42336302P | 2002-11-04 | 2002-11-04 | |
PCT/CA2003/001699 WO2004041251A1 (en) | 2002-11-04 | 2003-11-04 | Microcapsules having multiple shells and method for the preparation thereof |
US10/497,290 US20050067726A1 (en) | 2002-11-04 | 2003-11-04 | Microcapsules having multiple shells and method for the preparation thereof |
US12/642,303 US20100092571A1 (en) | 2002-11-04 | 2009-12-18 | Microcapsules having multiple shells and method for the preparation thereof |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10497290 Continuation | 2003-11-04 | ||
PCT/CA2003/001699 Continuation WO2004041251A1 (en) | 2002-11-04 | 2003-11-04 | Microcapsules having multiple shells and method for the preparation thereof |
US10/497,290 Continuation US20050067726A1 (en) | 2002-11-04 | 2003-11-04 | Microcapsules having multiple shells and method for the preparation thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/009,418 Continuation US8900630B2 (en) | 2002-11-04 | 2011-01-19 | Microcapsules having multiple shells and method for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100092571A1 true US20100092571A1 (en) | 2010-04-15 |
Family
ID=32312648
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/497,290 Abandoned US20050067726A1 (en) | 2002-11-04 | 2003-11-04 | Microcapsules having multiple shells and method for the preparation thereof |
US12/642,303 Abandoned US20100092571A1 (en) | 2002-11-04 | 2009-12-18 | Microcapsules having multiple shells and method for the preparation thereof |
US13/009,418 Expired - Fee Related US8900630B2 (en) | 2002-11-04 | 2011-01-19 | Microcapsules having multiple shells and method for the preparation thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/497,290 Abandoned US20050067726A1 (en) | 2002-11-04 | 2003-11-04 | Microcapsules having multiple shells and method for the preparation thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/009,418 Expired - Fee Related US8900630B2 (en) | 2002-11-04 | 2011-01-19 | Microcapsules having multiple shells and method for the preparation thereof |
Country Status (16)
Country | Link |
---|---|
US (3) | US20050067726A1 (en) |
EP (1) | EP1575561B1 (en) |
JP (1) | JP4833553B2 (en) |
KR (2) | KR20110112481A (en) |
CN (1) | CN100536828C (en) |
AT (1) | ATE470436T1 (en) |
AU (1) | AU2003283101B2 (en) |
BR (1) | BRPI0315977B8 (en) |
CA (1) | CA2471821C (en) |
DE (1) | DE60332958D1 (en) |
DK (1) | DK1575561T3 (en) |
ES (1) | ES2347045T3 (en) |
HK (1) | HK1084054A1 (en) |
MX (1) | MX272648B (en) |
NZ (1) | NZ539777A (en) |
WO (1) | WO2004041251A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011018716A1 (en) * | 2011-04-26 | 2012-10-31 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Microcapsule useful for micro-encapsulation, comprises an outer sheath and a volume of an antifreeze agent, which is enclosed by the outer sheath |
US9226524B2 (en) | 2010-03-26 | 2016-01-05 | Philip Morris Usa Inc. | Biopolymer foams as filters for smoking articles |
WO2022055069A1 (en) * | 2020-09-10 | 2022-03-17 | 서울대학교산학협력단 | Multifunctional microcapsule composition and preparation method therefor |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60112769T2 (en) * | 2000-09-08 | 2006-06-08 | San-Ei Gen F.F.I., Inc., Toyonaka | Tetraphenylbacteriochlorin derivatives and compositions containing them |
US6974592B2 (en) | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
ES2347045T3 (en) | 2002-11-04 | 2010-10-25 | Ocean Nutrition Canada Limited | MICROCAPSULES THAT HAVE MULTIPLE CORTEZAS, AND METHOD FOR THEIR PREPARATION. |
JP4926707B2 (en) | 2003-08-22 | 2012-05-09 | ダニスコ エイ/エス | Encapsulated antibacterial material |
EP1662870A1 (en) * | 2003-08-22 | 2006-06-07 | Danisco A/S | Encapsulated antimicrobial material |
GB2388581A (en) * | 2003-08-22 | 2003-11-19 | Danisco | Coated aqueous beads |
ES2235642B2 (en) * | 2003-12-18 | 2006-03-01 | Gat Formulation Gmbh | CONTINUOUS MULTI-MICROENCAPSULATION PROCESS FOR THE IMPROVEMENT OF STABILITY AND STORAGE OF BIOLOGICALLY ACTIVE INGREDIENTS. |
US6969530B1 (en) | 2005-01-21 | 2005-11-29 | Ocean Nutrition Canada Ltd. | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof |
US8034450B2 (en) | 2005-01-21 | 2011-10-11 | Ocean Nutrition Canada Limited | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof |
EP1848729A2 (en) * | 2005-01-27 | 2007-10-31 | Ocean Nutrition Canada Limited | Chromium-fatty acid compounds and methods of making and using thereof |
EP1899453B1 (en) | 2005-06-07 | 2013-12-18 | Ocean Nutrition Canada Limited | Eukaryotic microorganisms for producing lipids and antioxidants |
US9968120B2 (en) * | 2006-05-17 | 2018-05-15 | Dsm Nutritional Products Ag | Homogenized formulations containing microcapsules and methods of making and using thereof |
BRPI0612633A2 (en) * | 2005-07-07 | 2016-11-29 | Ocean Nutrition Canada Ltd | food articles with dispensing devices and methods for their preparation |
US7977498B2 (en) | 2005-08-26 | 2011-07-12 | Ocean Nutrition Canada Limited | Reduction of sterols and other compounds from oils |
PE20070482A1 (en) | 2005-08-26 | 2007-06-08 | Ocean Nutrition Canada Ltd | METHOD TO REMOVE AND / OR REDUCE STEROLS FROM OILS |
DE602006006695D1 (en) * | 2005-08-30 | 2009-06-18 | Firmenich & Cie | ENCAPSULATED ACTIVE SUBSTANCES, METHOD FOR PREPARATION AND THEIR USE |
US9693967B2 (en) | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
EP1931387A4 (en) * | 2005-09-07 | 2012-07-11 | Southwest Res Inst | Biodegradable microparticle pharmaceutical formulations exhibiting improved release rates |
US7485609B2 (en) * | 2005-09-29 | 2009-02-03 | Kimberly-Clark Worldwide, Inc. | Encapsulated liquid cleanser |
US7614812B2 (en) * | 2005-09-29 | 2009-11-10 | Kimberly-Clark Worldwide, Inc. | Wiper with encapsulated agent |
US7678399B2 (en) | 2005-12-05 | 2010-03-16 | Bunge Oils, Inc. | Phytosterol containing deep-fried foods and methods with health promoting characteristics |
US7442439B2 (en) * | 2005-12-28 | 2008-10-28 | Kimberly-Clark Worldwide, Inc. | Microencapsulated heat delivery vehicles |
US20070145618A1 (en) * | 2005-12-28 | 2007-06-28 | Kimberly-Clark Worldwide, Inc. | Methods of making microencapsulated delivery vehicles |
US20070149435A1 (en) * | 2005-12-28 | 2007-06-28 | Kimberly-Clark Worldwide, Inc. | Cleansing composition including microencapsulated delivery vehicles |
US20070148459A1 (en) * | 2005-12-28 | 2007-06-28 | Kimberly-Clark Worldwide, Inc. | Microencapsulated delivery vehicles |
US20070202185A1 (en) * | 2005-12-28 | 2007-08-30 | Kimberly-Clark Worldwide, Inc. | Microencapsulated Delivery Vehicles Having Fugitive Layers |
US20070148448A1 (en) * | 2005-12-28 | 2007-06-28 | Kimberly-Clark Worldwide, Inc. | Microencapsulated delivery vehicles including cooling agents |
US7914891B2 (en) | 2005-12-28 | 2011-03-29 | Kimberly-Clark Worldwide, Inc. | Wipes including microencapsulated delivery vehicles and phase change materials |
US20070148446A1 (en) * | 2005-12-28 | 2007-06-28 | Kimberly-Clark Worldwide, Inc. | Wipes including microencapsulated delivery vehicles and processes of producing the same |
US20070145619A1 (en) * | 2005-12-28 | 2007-06-28 | Kimberly-Clark Worldwide, Inc. | Processes for producing microencapsulated delivery vehicles |
WO2007120500A2 (en) | 2006-04-07 | 2007-10-25 | Ocean Nutrition Canada Ltd. | Emulsions and microcapsules with substances having low interfacial tension, methods of making and using thereof |
US7497351B2 (en) | 2006-05-30 | 2009-03-03 | Kimberly-Clark Worldwide, Inc. | Wet wipe dispensing system |
US7648046B2 (en) * | 2006-05-30 | 2010-01-19 | Kimberly-Clark Worldwide, Inc. | Dispensing system for dispensing warm wet wipes |
US7654412B2 (en) * | 2006-05-30 | 2010-02-02 | Kimberly-Clark Worldwide, Inc. | Wet wipe dispensing system for dispensing warm wet wipes |
EP2040682B1 (en) | 2006-06-05 | 2017-07-26 | DSM Nutritional Products AG | Microcapsules with improved shells |
US8221809B2 (en) * | 2006-06-22 | 2012-07-17 | Martek Biosciences Corporation | Encapsulated labile compound compositions and methods of making the same |
US9023616B2 (en) | 2006-08-01 | 2015-05-05 | Dsm Nutritional Products Ag | Oil producing microbes and method of modification thereof |
US9032971B2 (en) | 2006-11-15 | 2015-05-19 | Philip Morris Usa Inc. | Moist tobacco product and method of making |
US8192841B2 (en) * | 2006-12-14 | 2012-06-05 | Kimberly-Clark Worldwide, Inc. | Microencapsulated delivery vehicle having an aqueous core |
EP2124905B1 (en) * | 2007-01-10 | 2016-09-07 | DSM Nutritional Products AG | Microcapsules including pea protein |
CN101641022A (en) * | 2007-02-13 | 2010-02-03 | S-生物技术控股有限责任公司 | Diet product comprising alginate |
US8356606B2 (en) * | 2007-06-01 | 2013-01-22 | Philip Morris Usa Inc. | Production of micronized encapsulated tobacco particles for tobacco flavor delivery from an oral pouch |
WO2009004488A2 (en) | 2007-06-08 | 2009-01-08 | Philip Morris Products S.A. | Capsule clusters for oral consumption |
WO2008157629A1 (en) * | 2007-06-19 | 2008-12-24 | Martek Biosciences Corporation | Microencapsulating compositions, methods of making, methods of using and products thereof |
US9332774B2 (en) * | 2007-06-27 | 2016-05-10 | Bunge Oils, Inc. | Microencapsulated oil product and method of making same |
WO2009016091A1 (en) * | 2007-08-01 | 2009-02-05 | Unilever Plc | Coated particles |
US8312886B2 (en) * | 2007-08-09 | 2012-11-20 | Philip Morris Usa Inc. | Oral tobacco product having a hydrated membrane coating and a high surface area |
US9186640B2 (en) * | 2007-08-28 | 2015-11-17 | Pepsico, Inc. | Delivery and controlled release of encapsulated lipophilic nutrients |
US20100272859A1 (en) * | 2007-08-28 | 2010-10-28 | Pepsico, Inc. | Delivery and controlled release of encapsulated water-insoluble flavorants |
US8469037B2 (en) | 2008-02-08 | 2013-06-25 | Philip Morris Usa Inc. | Pre-portioned moist product and method of making |
US7924142B2 (en) * | 2008-06-30 | 2011-04-12 | Kimberly-Clark Worldwide, Inc. | Patterned self-warming wipe substrates |
US20100028503A1 (en) * | 2008-07-30 | 2010-02-04 | Jimbay Peter Loh | Simultaneous Multiple Acervation Process |
US8551517B2 (en) | 2008-12-16 | 2013-10-08 | Kimberly-Clark Worldwide, Inc. | Substrates providing multiple releases of active agents |
EP2379047B1 (en) | 2008-12-18 | 2017-03-15 | Firmenich S.A. | Microcapsules and uses thereof |
US9167835B2 (en) | 2008-12-30 | 2015-10-27 | Philip Morris Usa Inc. | Dissolvable films impregnated with encapsulated tobacco, tea, coffee, botanicals, and flavors for oral products |
CN102300473A (en) * | 2009-01-30 | 2011-12-28 | 荷兰联合利华有限公司 | Oil-in-water emulsions |
US9167847B2 (en) | 2009-03-16 | 2015-10-27 | Philip Morris Usa Inc. | Production of coated tobacco particles suitable for usage in a smokeless tobacoo product |
US9687023B2 (en) * | 2009-10-09 | 2017-06-27 | Philip Morris Usa Inc. | Moist smokeless tobacco product for oral usage having on a portion of the outer surface at least one friction reducing strip that provides texture during use |
US8539958B2 (en) * | 2009-10-13 | 2013-09-24 | Philip Morris Usa Inc. | Oral moist smokeless tobacco products with net-structured gel coating and methods of making |
JP5560017B2 (en) * | 2009-10-13 | 2014-07-23 | 旭化成ケミカルズ株式会社 | Tablets containing multi-core microcapsules containing fatty acids, triglycerides or mixtures thereof and process for producing the same |
US8663671B2 (en) | 2009-11-05 | 2014-03-04 | Philip Morris Usa Inc. | Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity |
RU2592876C2 (en) * | 2010-03-26 | 2016-07-27 | Филип Моррис Продактс С.А. | Encapsulation of solid flavourant using complex coacervation and gelation technology |
AR081743A1 (en) * | 2010-03-26 | 2012-10-17 | Philip Morris Prod | MANUFACTURE OF NUCLEUS CAPSULES / CAPARAZON OF DIFFERENT GEOMETRICS AND TREATMENT FROM THE SAME |
CN102821625B (en) | 2010-03-26 | 2016-11-23 | 菲利普莫里斯生产公司 | There is the smoking article of heat-resisting sheet material |
US20130196173A1 (en) * | 2010-04-09 | 2013-08-01 | Postech Academy-Industry Foundation | Organic Corrosion Inhibitor-Embedded Polymer Capsule, Preparation Method Thereof, Composition Containing Same, and Surface Treated Steel Sheet Using Same |
MX364560B (en) * | 2010-09-20 | 2019-05-02 | Spi Pharma Inc Star | Microencapsulation process and product. |
FR2969907B1 (en) * | 2010-12-31 | 2014-03-07 | Capsum | SERIES OF CAPSULES COMPRISING AT LEAST ONE INTERNAL PHASE DROP IN AN INTERMEDIATE PHASE DROP AND METHOD OF MANUFACTURING THE SAME |
CN102526124B (en) * | 2011-01-31 | 2013-11-20 | 成都科尔医药技术有限公司 | Traditional Chinese medicinal powder and preparation method thereof |
RU2013156437A (en) * | 2011-06-07 | 2015-07-20 | СПАЙ Груп Лтд. | COMPOSITION AND METHODS FOR IMPROVING STABILITY AND EXTENDING THE PERIOD OF STORAGE OF SENSITIVE FOOD ADDITIVES AND FOOD PRODUCTS FROM THEM |
US20130004617A1 (en) * | 2011-07-01 | 2013-01-03 | Pepsico, Inc. | Coacervate complexes, methods and food products |
CN102977857B (en) * | 2011-09-06 | 2015-12-09 | 比亚迪股份有限公司 | A kind of microcapsules of storing energy through phase change and preparation method thereof |
KR101978361B1 (en) * | 2011-09-13 | 2019-05-14 | 리켄 비타민 가부시키가이샤 | Method for manufacturing multicore gelatin microcapsule |
US20130095210A1 (en) * | 2011-10-13 | 2013-04-18 | Pepsico, Inc. | Complex Coacervates and Aqueous Dispersions of Complex Coacervates and Methods of Making Same |
RU2592572C2 (en) | 2012-05-21 | 2016-07-27 | ДСМ Ньютришнл Продактс АГ | Composition and method of increasing stability of additives to food products |
US8617610B2 (en) | 2012-05-21 | 2013-12-31 | Dsm Nutritional Products Ag | Compositions and methods for increasing the stability of food product additives |
GB201210156D0 (en) * | 2012-06-08 | 2012-07-25 | Imerys Minerals Ltd | Microcapsules |
WO2014022505A1 (en) | 2012-07-31 | 2014-02-06 | Dsm Nutritional Products Ag | Refinement of oils using green tea extract antioxidants |
US10034819B2 (en) * | 2012-09-24 | 2018-07-31 | Firmenich Sa | Multilayered core/shell microcapsules |
KR102152751B1 (en) * | 2012-09-28 | 2020-09-07 | (주)아모레퍼시픽 | Microcapsule containing glycoprotein of plant origin |
FR2996418B1 (en) * | 2012-10-09 | 2015-05-29 | Seppic Sa | FOOD COMPOSITIONS COMPRISING CAPSULES OBTAINED BY COACERVATION NOT IMPLEMENTING TOXIC RETICULANT |
FR2996466B1 (en) * | 2012-10-09 | 2015-06-05 | Seppic Sa | METHOD OF ENCAPSULATION BY COACERVATION NOT IMPLEMENTING TOXIC RETICULANT |
KR101362800B1 (en) * | 2012-10-16 | 2014-02-14 | 한국식품연구원 | Prolamine-positive ion complex contaning phytosterol and method thereof |
KR101766900B1 (en) | 2012-11-30 | 2017-08-17 | (주)케이피티 | Pressure-Breakable Microcapsules containing scrubs, preparation and use thereof |
PT2970926T (en) | 2013-03-13 | 2018-03-22 | Dsm Nutritional Products Ag | Engineering microorganisms |
KR101691644B1 (en) * | 2013-12-04 | 2017-01-03 | 주식회사 씨앤지 | The functional material containing the Polymeric microcapsules and its manufacturing method |
CN103769020B (en) * | 2014-01-21 | 2016-03-02 | 华南理工大学 | A kind of double-core microcapsules and preparation method thereof and application |
US9528983B2 (en) * | 2014-05-12 | 2016-12-27 | Anna Merritt Holmes | Physicochemical modification and application of alginate gels for the controlled release of reagents in classical solution assays and microfluidic assays |
CA2957368C (en) | 2014-08-05 | 2023-05-23 | Advanced Bionutrition Corp. | Encapsulation of hydrophobic biologically active compounds |
US10052287B2 (en) | 2014-08-07 | 2018-08-21 | Nestec S.A. | Delivery system comprising a core and a digestible polymer shell |
FR3031914B1 (en) * | 2015-01-27 | 2019-06-07 | Calyxia | ENCAPSULATION METHOD |
US9334430B1 (en) * | 2015-05-29 | 2016-05-10 | Sirrus, Inc. | Encapsulated polymerization initiators, polymerization systems and methods using the same |
JP6651525B2 (en) * | 2015-07-31 | 2020-02-19 | 株式会社ジーシー | Composition for tooth bleaching |
CN105286011B (en) * | 2015-09-18 | 2018-05-15 | 华南理工大学 | A kind of soluble soybean polysaccharide-soybean protein-curcumin complex and preparation and application |
KR101722067B1 (en) * | 2016-01-18 | 2017-04-07 | 주식회사 씨앤지 | The functional material containing the Polymeric microcapsules and its manufacturing method |
CN105558354B (en) * | 2016-01-26 | 2019-08-20 | 武汉轻工大学 | Feeding fish oil micro-capsule and its preparation process |
US11419350B2 (en) | 2016-07-01 | 2022-08-23 | Corbion Biotech, Inc. | Feed ingredients comprising lysed microbial cells |
US10729168B2 (en) * | 2016-08-22 | 2020-08-04 | Incredible Foods, Inc. | Manufactured fruit compositions and methods of making |
CN110072986B (en) * | 2016-11-01 | 2023-04-04 | 诺维信公司 | Multi-core particles |
DE102017111444A1 (en) | 2017-05-24 | 2018-11-29 | Henkel Ag & Co. Kgaa | Microcapsule system for polysensory scent effects |
US20180346648A1 (en) * | 2017-05-30 | 2018-12-06 | International Flavors & Fragrances Inc. | Branched polyethyleneimine microcapsules |
CN107183767B (en) * | 2017-06-08 | 2018-06-22 | 北京工商大学 | A kind of monokaryon edible oil and fat microcapsules and preparation method thereof |
US20190070078A1 (en) * | 2017-09-05 | 2019-03-07 | Robb Akridge | Truffle configured cosmetic article |
CN111770788B (en) * | 2018-03-13 | 2023-07-25 | 诺维信公司 | Microencapsulation using amino sugar oligomers |
DE102019123274A1 (en) | 2019-08-30 | 2021-03-04 | Carl Freudenberg Kg | Cleaning article that contains microcapsules |
CN117598506A (en) | 2019-09-12 | 2024-02-27 | 努利希尔有限公司 | Controlled release core-shell particles and suspensions comprising the same |
US11660578B2 (en) | 2019-10-15 | 2023-05-30 | Rea Innovations, Inc. | Systems and methods for blending solid-shell cosmetic ingredient capsules and blendable cosmetic ingredient capsules |
US11497692B2 (en) | 2019-10-15 | 2022-11-15 | Rea Innovations, Inc. | Systems and methods for blending solid-shell cosmetic ingredient capsules and blendable cosmetic ingredient capsules |
FR3102912B1 (en) * | 2019-11-07 | 2024-06-14 | Huddle Corp | Food or dietary supplement for livestock |
KR20220114618A (en) | 2019-12-17 | 2022-08-17 | 9286-3620 퀘벡 인크. | Oral delivery system based on in situ formation of protein/polysaccharide coacervates |
KR102303886B1 (en) * | 2019-12-26 | 2021-09-23 | 한국과학기술원 | Sensor-type microcapsules with triple droplet-based double shell and preparation method thereof |
CN111955735B (en) * | 2020-07-30 | 2022-04-29 | 中国农业大学 | Preparation method of phytosterol microcapsule |
KR20220075022A (en) * | 2020-11-26 | 2022-06-07 | (주) 에이치엔에이파마켐 | Method for preparing multilayered spherical particles and cosmetic composition comprising multilayered spherical particles prepared therefrom |
DE102021205957A1 (en) * | 2021-06-11 | 2022-12-15 | Koehler Innovation & Technology Gmbh | Color neutral degradable microcapsules |
GB202110132D0 (en) | 2021-07-14 | 2021-08-25 | Cpl Aromas Ltd | Microcapsules and methods for preparing microcapsules |
WO2023239944A2 (en) * | 2022-06-10 | 2023-12-14 | Phyto Tech Corp. | Biodegradable fragrance and/or flavor-loaded microcapsules |
CN115500516B (en) * | 2022-09-28 | 2023-11-07 | 江苏恒康生物科技有限公司 | Probiotics slow-release carrier, slow-release dripping pill, and preparation method and application thereof |
Citations (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2800457A (en) * | 1953-06-30 | 1957-07-23 | Ncr Co | Oil-containing microscopic capsules and method of making them |
US3041289A (en) * | 1959-01-02 | 1962-06-26 | Ncr Co | Method of making walled clusters of capsules |
US3179600A (en) * | 1960-03-10 | 1965-04-20 | Ncr Co | Minute color-forming capsules and record material provided with such |
US3526682A (en) * | 1966-08-23 | 1970-09-01 | Pfizer & Co C | Microencapsulation of pharmaceuticals |
US3697437A (en) * | 1970-05-27 | 1972-10-10 | Ncr Co | Encapsulation process by complex coacervation using inorganic polyphosphates and organic hydrophilic polymeric material |
US4010038A (en) * | 1974-04-10 | 1977-03-01 | Kanzaki Paper Manufacturing Co., Ltd. | Process for producing microcapsules |
US4217370A (en) * | 1977-08-25 | 1980-08-12 | Blue Wing Corporation | Lipid-containing feed supplements and foodstuffs |
US4219439A (en) * | 1977-01-28 | 1980-08-26 | Kanzaki Paper Manufacturing Co., Ltd. | Method of making oil-containing microcapsules |
US4222891A (en) * | 1977-08-17 | 1980-09-16 | Kanzaki Paper Mfg. Co., Ltd. | Method of making oil-containing microcapsules |
US4273672A (en) * | 1971-08-23 | 1981-06-16 | Champion International Corporation | Microencapsulation process |
US4670247A (en) * | 1983-07-05 | 1987-06-02 | Hoffman-Laroche Inc. | Process for preparing fat-soluble vitamin active beadlets |
US4695466A (en) * | 1983-01-17 | 1987-09-22 | Morishita Jintan Co., Ltd. | Multiple soft capsules and production thereof |
US4744933A (en) * | 1984-02-15 | 1988-05-17 | Massachusetts Institute Of Technology | Process for encapsulation and encapsulated active material system |
US4749620A (en) * | 1984-02-15 | 1988-06-07 | Massachusetts Institute Of Technology | Encapsulated active material system |
US4808408A (en) * | 1983-05-11 | 1989-02-28 | Bend Research, Inc. | Microcapsules prepared by coacervation |
US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US4867986A (en) * | 1987-07-17 | 1989-09-19 | Pharmachem Laboratories, Inc. | Dry stabilized microemulsified omega-three acid-containing oils |
US4891172A (en) * | 1979-10-15 | 1990-01-02 | Mitsubishi Paper Mills, Ltd. | Process for producing double-capsules |
US4895725A (en) * | 1987-08-24 | 1990-01-23 | Clinical Technologies Associates, Inc. | Microencapsulation of fish oil |
US4923855A (en) * | 1983-07-08 | 1990-05-08 | The William Seroy Group | Synthetic GTF chromium material and process therefor |
US4954492A (en) * | 1983-07-08 | 1990-09-04 | The William Seroy Group | Synthetic GTF chromium material for decreasing blood lipid levels and process therefor |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4964624A (en) * | 1987-06-23 | 1990-10-23 | Hutchinson | Resilient supports with composite cables embedded in elastomeric material |
US5035896A (en) * | 1988-06-15 | 1991-07-30 | Warner-Lambert Company | Water insoluble drugs coated by coacervated fish gelatin |
US5051304A (en) * | 1986-12-18 | 1991-09-24 | Societe Anonyme: Mero Rousselot Satia | Microcapsules based on gelatin and polysaccharides and process for obtaining same |
US5059622A (en) * | 1989-08-29 | 1991-10-22 | Biosyn, Inc. | Method for reducing blood pressure levels in hypertensive persons |
US5130061A (en) * | 1987-05-28 | 1992-07-14 | Innova Di Ridolfi Flora & C. S.A.S. | Process for the extraction of polyunsaturated fatty acid esters from fish oils |
US5156956A (en) * | 1987-03-04 | 1992-10-20 | Ajinomoto Co., Inc. | Transgultaminase |
US5194615A (en) * | 1983-07-08 | 1993-03-16 | The William Seroy Group | Synthetic GTF chromium nicotinate material and its preparation |
US5204029A (en) * | 1989-09-25 | 1993-04-20 | Morgan Food Products, Inc. | Methods of encapsulating liquids in fatty matrices, and products thereof |
US5330778A (en) * | 1988-09-19 | 1994-07-19 | Opta Food Ingredients, Inc. | Hydrophobic protein microparticles |
US5356636A (en) * | 1991-12-14 | 1994-10-18 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form, and the preparation thereof |
US5378413A (en) * | 1993-01-21 | 1995-01-03 | The United States Of America As Represented By The Secretary Of The Navy | Process for preparing microcapsules having gelatin walls crosslinked with quinone |
US5428014A (en) * | 1993-08-13 | 1995-06-27 | Zymogenetics, Inc. | Transglutaminase cross-linkable polypeptides and methods relating thereto |
US5456985A (en) * | 1990-06-13 | 1995-10-10 | Zgoulli; Slim | Microcapsules of oily liquid |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5603961A (en) * | 1992-10-01 | 1997-02-18 | Tanabe Seiyaku Co., Ltd. | Sustained release multi-core microsphere preparation and method for producing the same |
US5603952A (en) * | 1994-12-30 | 1997-02-18 | Tastemaker | Method of encapsulating food or flavor particles using warm water fish gelatin, and capsules produced therefrom |
US5670209A (en) * | 1995-04-24 | 1997-09-23 | Brite-Line Technologies, Inc. | High brightness durable retro-reflecting microspheres and method of making the same |
US5700397A (en) * | 1992-06-16 | 1997-12-23 | Fuji Oil Co., Ltd. | Emulsifier, emulsion composition, and powder composition |
US5766637A (en) * | 1996-10-08 | 1998-06-16 | University Of Delaware | Microencapsulation process using supercritical fluids |
US5780056A (en) * | 1996-05-10 | 1998-07-14 | Lion Corporation | Microcapsules of the multi-core structure containing natural carotenoid |
US5827531A (en) * | 1994-12-02 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microcapsules and methods for making |
US5872140A (en) * | 1993-07-23 | 1999-02-16 | Research Institute For Medicine And Chemistry, Inc. | Vitamin D analogues |
US5993851A (en) * | 1993-07-28 | 1999-11-30 | Pharmaderm Laboratories, Ltd. | Method for preparing biphasic multilamellar lipid vesicles |
US6019998A (en) * | 1993-05-18 | 2000-02-01 | Canon Kabushiki Kaisha | Membrane structure |
US6020200A (en) * | 1995-03-03 | 2000-02-01 | Metabolex, Inc. | Encapsulation compositions and methods |
US6039901A (en) * | 1997-01-31 | 2000-03-21 | Givaudan Roure Flavors Corporation | Enzymatically protein encapsulating oil particles by complex coacervation |
US6063820A (en) * | 1997-03-20 | 2000-05-16 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Medical food for diabetics |
US6103378A (en) * | 1998-11-23 | 2000-08-15 | The Mead Company | Capsules having discrete solvent/color former and diluent capsule encapsulated phases |
US6106875A (en) * | 1997-10-08 | 2000-08-22 | Givaudan Roure (International) Sa | Method of encapsulating flavors and fragrances by controlled water transport into microcapsules |
US6221401B1 (en) * | 1996-12-02 | 2001-04-24 | The Regents Of The University Of California | Bilayer structure which encapsulates multiple containment units and uses thereof |
US6234464B1 (en) * | 1998-07-08 | 2001-05-22 | K.D. Pharma Bexbech Gmbh | Microencapsulated unsaturated fatty acid or fatty acid compound or mixture of fatty acids and/fatty acid compounds |
US6274174B1 (en) * | 1997-10-31 | 2001-08-14 | Nisshinbo Industries, Inc. | Aggregates of spherical multivalent metal alginate microparticles and methods of making them |
US6300377B1 (en) * | 2001-02-22 | 2001-10-09 | Raj K. Chopra | Coenzyme Q products exhibiting high dissolution qualities |
US6328995B1 (en) * | 1999-09-24 | 2001-12-11 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form and process for their production |
US20020031553A1 (en) * | 2000-05-03 | 2002-03-14 | Nora Moyano | Manufacturing process of microcapsules for sustained release of water soluble peptides |
US6365176B1 (en) * | 2000-08-08 | 2002-04-02 | Functional Foods, Inc. | Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy |
US6417233B1 (en) * | 1998-10-21 | 2002-07-09 | Sigma-Tau Healthscience S.P.A. | Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiguinones and methods of using same |
US6441050B1 (en) * | 2000-08-29 | 2002-08-27 | Raj K. Chopra | Palatable oral coenzyme Q liquid |
US6528165B2 (en) * | 1999-08-17 | 2003-03-04 | Luminex Corporation | Encapsulation of discrete quanta of fluorescent particles |
US20030044380A1 (en) * | 2001-07-19 | 2003-03-06 | Zhu Yong Hua | Adhesive including medicament |
US6534091B1 (en) * | 1999-07-02 | 2003-03-18 | Cognis Iberia S. L. | Microcapsules |
US6544926B1 (en) * | 2001-10-11 | 2003-04-08 | Appleton Papers Inc. | Microcapsules having improved printing and efficiency |
US20030091654A1 (en) * | 2000-09-21 | 2003-05-15 | Katz David P. | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US20030133886A1 (en) * | 2001-11-15 | 2003-07-17 | Xerox Corporation | Photoprotective and lightfastness-enhancing siloxanes |
US6630157B1 (en) * | 1997-07-22 | 2003-10-07 | Viatris Gmbh & Co. Kg. | Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
US6652891B2 (en) * | 2001-12-12 | 2003-11-25 | Herbasway Laboratories, Llc | Co-enzyme Q10 dietary supplement |
US20040106591A1 (en) * | 2002-11-22 | 2004-06-03 | Pacioretty Linda M. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
US20050019416A1 (en) * | 2002-04-11 | 2005-01-27 | Ocean Nutrition Canada Ltd. | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US6969530B1 (en) * | 2005-01-21 | 2005-11-29 | Ocean Nutrition Canada Ltd. | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof |
US6972592B2 (en) * | 2003-11-24 | 2005-12-06 | Lsi Logic Corporation | Self-timed scan circuit for ASIC fault testing |
US20070059340A1 (en) * | 2005-09-09 | 2007-03-15 | Anthony Bello | Omega-3 Fatty Acids Encapsulated In Zein Coatings and Food Products Incorporating the Same |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1035319B (en) | 1952-05-07 | 1958-07-31 | Hoffmann La Roche | Process for the production of a powder containing vitamins |
BE530010A (en) * | 1953-06-30 | |||
NL129921C (en) * | 1958-12-31 | |||
SE344686B (en) | 1968-01-29 | 1972-05-02 | Ncr | |
US4232084A (en) * | 1978-01-25 | 1980-11-04 | Thalatta, Inc. | Sheets containing microencapsulated color-coded micromagnets |
GB2075458B (en) * | 1980-04-21 | 1983-06-02 | Nicholas Pty Ltd | Encapsulation of indomethacin |
US4485172A (en) * | 1981-01-19 | 1984-11-27 | Cpc International Inc. | Multistage process for the preparation of fats and oils |
NZ199218A (en) | 1981-01-19 | 1985-03-20 | Cpc International Inc | Production of fats and oils by cultivating yeast cells |
GB2115768A (en) | 1982-02-11 | 1983-09-14 | Kms Fusion Inc | Containment of hazardous fluids |
JPS58149645U (en) | 1982-03-31 | 1983-10-07 | 東海ゴム工業株式会社 | Cylindrical torsional damper |
JPS61172807A (en) | 1985-01-25 | 1986-08-04 | Ajinomoto Co Inc | Cosmetic |
CH672330A5 (en) * | 1986-02-04 | 1989-11-15 | Zinser Textilmaschinen Gmbh | |
EP0301777A1 (en) | 1987-07-28 | 1989-02-01 | Queen's University At Kingston | Multiple membrane microencapsulation |
WO1992011083A1 (en) | 1987-09-28 | 1992-07-09 | Redding Bruce K Jr | Apparatus and method for making microcapsules |
EP0434760B1 (en) | 1988-09-19 | 1994-01-12 | Opta Food Ingredients, Inc. | Hydrophobic protein microparticles and preparation thereof |
JP2619933B2 (en) | 1988-09-21 | 1997-06-11 | ニッピゼラチン工業株式会社 | Method for producing high polymerization degree gelatin |
US4946624A (en) * | 1989-02-27 | 1990-08-07 | The Procter & Gamble Company | Microcapsules containing hydrophobic liquid core |
CA2024587A1 (en) * | 1989-09-05 | 1991-03-06 | Bernard Ecanow | Drug delivery compositions based on biological cells or components thereof and methods |
FI905333A0 (en) | 1989-10-31 | 1990-10-29 | Warner Lambert Co | FOERKAPSLAT BRUKSSYSTEM FOER SOETNINGS- OCH AROMMEDEL OCH FOERFARANDE FOER DESS FRAMSTAELLNING. |
AU642932B2 (en) | 1989-11-06 | 1993-11-04 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
US5013569A (en) * | 1990-05-21 | 1991-05-07 | Century Laboratories, Inc. | Infant formula |
US5759599A (en) * | 1992-03-30 | 1998-06-02 | Givaudan Roure Flavors Corporation | Method of flavoring and mechanically processing foods with polymer encapsulated flavor oils |
PT644771E (en) | 1992-06-11 | 2002-12-31 | Alkermes Inc | ERITROPOIETIN DRUG DELIVERY SYSTEM |
GB9306808D0 (en) * | 1993-04-01 | 1993-05-26 | Ciba Geigy Ag | Coated microparticle agglomerates |
US5997863A (en) * | 1994-07-08 | 1999-12-07 | Ibex Technologies R And D, Inc. | Attenuation of wound healing processes |
ES2218553T3 (en) | 1994-10-11 | 2004-11-16 | Ajinomoto Co., Inc. | STABILIZED TRANSGLUTAMINASE AND ENZYMATIC PREPARATION CONTAINING IT. |
WO1997013416A1 (en) * | 1995-10-12 | 1997-04-17 | Mccormick & Company, Inc. | Double encapsulation process and flavorant compositions prepared thereby |
DE19600285C2 (en) | 1996-01-05 | 1998-10-15 | Stoever Adolf Bautex Kg | Curtain train |
US5834232A (en) | 1996-05-01 | 1998-11-10 | Zymogenetics, Inc. | Cross-linked gelatin gels and methods of making them |
JP3635801B2 (en) | 1996-08-01 | 2005-04-06 | 味の素株式会社 | Milk whey protein-containing powder and processed food using the same |
KR0173445B1 (en) * | 1996-09-17 | 1999-02-01 | 이능희 | Double layered capsule for cosmetics and cosmetic compositions containing the same |
DK0897970T3 (en) | 1997-08-22 | 2004-11-08 | Unilever Nv | Process for the preparation of stanol esters |
DE19801593A1 (en) | 1998-01-17 | 1999-07-22 | Henkel Kgaa | New cosmetic and pharmaceutical creams |
DE19838189A1 (en) | 1998-08-24 | 2000-03-02 | Basf Ag | Stable powdered vitamin and carotenoid preparations and process for their preparation |
JP2000244593A (en) * | 1999-02-22 | 2000-09-08 | Sony Corp | Reception equipment |
ZA200003120B (en) * | 1999-06-30 | 2001-01-02 | Givaudan Roure Int | Encapsulation of active ingredients. |
US6500463B1 (en) * | 1999-10-01 | 2002-12-31 | General Mills, Inc. | Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
CA2390864A1 (en) | 1999-11-18 | 2001-05-25 | Quest International B.V. | Stable, spray-dried composition in a carbohydrate substrate and process for obtaining said composition |
DE10001172A1 (en) | 2000-01-13 | 2001-07-26 | Max Planck Gesellschaft | Templating solid particles with polymer multilayers |
US6534926B1 (en) * | 2000-04-12 | 2003-03-18 | Tmc Enterprises, A Division Of Tasco Industries, Inc. | Portable fluorescent drop-light |
SE523211C2 (en) | 2000-04-26 | 2004-04-06 | Skaanemejerier Ekonomisk Foere | Lipid composition comprising a protective oil and a polyunsaturated fatty acid, emulsion containing such a composition and process for preparing the emulsion |
JP4695248B2 (en) | 2000-07-18 | 2011-06-08 | 小川香料株式会社 | Method for producing microcapsules with airtight coating |
WO2002096408A1 (en) | 2001-05-30 | 2002-12-05 | Laxdale Limited | Coenzyme q and eicosapentaenoic acid (epa) |
US20050027307A1 (en) * | 2001-07-16 | 2005-02-03 | Schwartz Herbert Eugene | Unitary surgical device and method |
EP1371410A1 (en) | 2002-06-14 | 2003-12-17 | NIZO food research | Complex coacervates containing whey proteins |
WO2003105606A1 (en) | 2002-06-18 | 2003-12-24 | Martek Biosciences Corporation | Stable emulsions of oils in aqueous solutions and methods for producing same |
CA2499423A1 (en) * | 2002-09-04 | 2004-03-18 | Niraj Vasisht | Microencapsulation of oxygen or water sensitive materials |
ES2347045T3 (en) | 2002-11-04 | 2010-10-25 | Ocean Nutrition Canada Limited | MICROCAPSULES THAT HAVE MULTIPLE CORTEZAS, AND METHOD FOR THEIR PREPARATION. |
EP1585592A1 (en) | 2002-12-18 | 2005-10-19 | Unilever N.V. | Complex coacervate encapsulate comprising lipophilic core |
EP1430947A1 (en) | 2002-12-21 | 2004-06-23 | Cognis Iberia, S.L. | Multicompartment microparticles with liquid crystalline cores |
GB0319071D0 (en) * | 2003-08-14 | 2003-09-17 | Avecia Ltd | Catalyst and process |
US20050118285A1 (en) * | 2003-10-23 | 2005-06-02 | L'oreal | O/W emulsion containing aloe vera, uses thereof, method for making |
US20070224216A1 (en) * | 2004-05-04 | 2007-09-27 | Jane Teas | Methods and Compositions Related to Antiviral Therapy Using Algae and Cyanobacteria |
WO2007005727A2 (en) * | 2005-07-01 | 2007-01-11 | Martek Biosciences Corporation | Microwaveable popcorn and methods of making |
US9968120B2 (en) * | 2006-05-17 | 2018-05-15 | Dsm Nutritional Products Ag | Homogenized formulations containing microcapsules and methods of making and using thereof |
BRPI0612633A2 (en) | 2005-07-07 | 2016-11-29 | Ocean Nutrition Canada Ltd | food articles with dispensing devices and methods for their preparation |
US20070078071A1 (en) * | 2005-09-30 | 2007-04-05 | Kaiping Lee | Spray dry capsule products and methods for preparing and using same |
US7803413B2 (en) | 2005-10-31 | 2010-09-28 | General Mills Ip Holdings Ii, Llc. | Encapsulation of readily oxidizable components |
US20090162509A1 (en) | 2005-11-14 | 2009-06-25 | Banken Hermanus Theodorus K M | Sterilised Nutritional Beverage |
US20070141211A1 (en) * | 2005-12-16 | 2007-06-21 | Solae, Llc | Encapsulated Phospholipid-Stabilized Oxidizable Material |
WO2007120500A2 (en) * | 2006-04-07 | 2007-10-25 | Ocean Nutrition Canada Ltd. | Emulsions and microcapsules with substances having low interfacial tension, methods of making and using thereof |
EP2040682B1 (en) * | 2006-06-05 | 2017-07-26 | DSM Nutritional Products AG | Microcapsules with improved shells |
JP2008015275A (en) * | 2006-07-06 | 2008-01-24 | Fuji Xerox Co Ltd | Electrophotographic photoreceptor, image forming apparatus and process cartridge |
JP5292899B2 (en) | 2008-04-02 | 2013-09-18 | セイコーエプソン株式会社 | Fluid ejection device |
JP5394273B2 (en) | 2010-02-03 | 2014-01-22 | 本田技研工業株式会社 | Hydrogen storage material and method for producing the same |
-
2003
- 2003-11-04 ES ES03773376T patent/ES2347045T3/en not_active Expired - Lifetime
- 2003-11-04 KR KR1020117022451A patent/KR20110112481A/en not_active Application Discontinuation
- 2003-11-04 MX MXPA05004859 patent/MX272648B/en active IP Right Grant
- 2003-11-04 EP EP03773376A patent/EP1575561B1/en not_active Expired - Lifetime
- 2003-11-04 AU AU2003283101A patent/AU2003283101B2/en not_active Ceased
- 2003-11-04 BR BRPI0315977A patent/BRPI0315977B8/en not_active IP Right Cessation
- 2003-11-04 CA CA002471821A patent/CA2471821C/en not_active Expired - Fee Related
- 2003-11-04 KR KR1020057007996A patent/KR101175774B1/en active IP Right Grant
- 2003-11-04 CN CNB2003801081294A patent/CN100536828C/en not_active Expired - Fee Related
- 2003-11-04 JP JP2004548984A patent/JP4833553B2/en not_active Expired - Fee Related
- 2003-11-04 NZ NZ539777A patent/NZ539777A/en not_active IP Right Cessation
- 2003-11-04 US US10/497,290 patent/US20050067726A1/en not_active Abandoned
- 2003-11-04 DK DK03773376.3T patent/DK1575561T3/en active
- 2003-11-04 DE DE60332958T patent/DE60332958D1/en not_active Expired - Lifetime
- 2003-11-04 AT AT03773376T patent/ATE470436T1/en active
- 2003-11-04 WO PCT/CA2003/001699 patent/WO2004041251A1/en active Application Filing
-
2006
- 2006-06-06 HK HK06106466.6A patent/HK1084054A1/en not_active IP Right Cessation
-
2009
- 2009-12-18 US US12/642,303 patent/US20100092571A1/en not_active Abandoned
-
2011
- 2011-01-19 US US13/009,418 patent/US8900630B2/en not_active Expired - Fee Related
Patent Citations (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2800457A (en) * | 1953-06-30 | 1957-07-23 | Ncr Co | Oil-containing microscopic capsules and method of making them |
US3041289A (en) * | 1959-01-02 | 1962-06-26 | Ncr Co | Method of making walled clusters of capsules |
US3179600A (en) * | 1960-03-10 | 1965-04-20 | Ncr Co | Minute color-forming capsules and record material provided with such |
US3526682A (en) * | 1966-08-23 | 1970-09-01 | Pfizer & Co C | Microencapsulation of pharmaceuticals |
US3697437A (en) * | 1970-05-27 | 1972-10-10 | Ncr Co | Encapsulation process by complex coacervation using inorganic polyphosphates and organic hydrophilic polymeric material |
US4273672A (en) * | 1971-08-23 | 1981-06-16 | Champion International Corporation | Microencapsulation process |
US4010038A (en) * | 1974-04-10 | 1977-03-01 | Kanzaki Paper Manufacturing Co., Ltd. | Process for producing microcapsules |
US4219439A (en) * | 1977-01-28 | 1980-08-26 | Kanzaki Paper Manufacturing Co., Ltd. | Method of making oil-containing microcapsules |
US4222891A (en) * | 1977-08-17 | 1980-09-16 | Kanzaki Paper Mfg. Co., Ltd. | Method of making oil-containing microcapsules |
US4217370A (en) * | 1977-08-25 | 1980-08-12 | Blue Wing Corporation | Lipid-containing feed supplements and foodstuffs |
US4891172A (en) * | 1979-10-15 | 1990-01-02 | Mitsubishi Paper Mills, Ltd. | Process for producing double-capsules |
US4695466A (en) * | 1983-01-17 | 1987-09-22 | Morishita Jintan Co., Ltd. | Multiple soft capsules and production thereof |
US4808408A (en) * | 1983-05-11 | 1989-02-28 | Bend Research, Inc. | Microcapsules prepared by coacervation |
US4670247A (en) * | 1983-07-05 | 1987-06-02 | Hoffman-Laroche Inc. | Process for preparing fat-soluble vitamin active beadlets |
US4954492A (en) * | 1983-07-08 | 1990-09-04 | The William Seroy Group | Synthetic GTF chromium material for decreasing blood lipid levels and process therefor |
US5194615A (en) * | 1983-07-08 | 1993-03-16 | The William Seroy Group | Synthetic GTF chromium nicotinate material and its preparation |
US4923855A (en) * | 1983-07-08 | 1990-05-08 | The William Seroy Group | Synthetic GTF chromium material and process therefor |
US4744933A (en) * | 1984-02-15 | 1988-05-17 | Massachusetts Institute Of Technology | Process for encapsulation and encapsulated active material system |
US4749620A (en) * | 1984-02-15 | 1988-06-07 | Massachusetts Institute Of Technology | Encapsulated active material system |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US5051304A (en) * | 1986-12-18 | 1991-09-24 | Societe Anonyme: Mero Rousselot Satia | Microcapsules based on gelatin and polysaccharides and process for obtaining same |
US5156956A (en) * | 1987-03-04 | 1992-10-20 | Ajinomoto Co., Inc. | Transgultaminase |
US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US5130061A (en) * | 1987-05-28 | 1992-07-14 | Innova Di Ridolfi Flora & C. S.A.S. | Process for the extraction of polyunsaturated fatty acid esters from fish oils |
US4964624A (en) * | 1987-06-23 | 1990-10-23 | Hutchinson | Resilient supports with composite cables embedded in elastomeric material |
US4867986A (en) * | 1987-07-17 | 1989-09-19 | Pharmachem Laboratories, Inc. | Dry stabilized microemulsified omega-three acid-containing oils |
US4895725A (en) * | 1987-08-24 | 1990-01-23 | Clinical Technologies Associates, Inc. | Microencapsulation of fish oil |
US5035896A (en) * | 1988-06-15 | 1991-07-30 | Warner-Lambert Company | Water insoluble drugs coated by coacervated fish gelatin |
US5330778A (en) * | 1988-09-19 | 1994-07-19 | Opta Food Ingredients, Inc. | Hydrophobic protein microparticles |
US5059622A (en) * | 1989-08-29 | 1991-10-22 | Biosyn, Inc. | Method for reducing blood pressure levels in hypertensive persons |
US5204029A (en) * | 1989-09-25 | 1993-04-20 | Morgan Food Products, Inc. | Methods of encapsulating liquids in fatty matrices, and products thereof |
US5456985A (en) * | 1990-06-13 | 1995-10-10 | Zgoulli; Slim | Microcapsules of oily liquid |
US5356636A (en) * | 1991-12-14 | 1994-10-18 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form, and the preparation thereof |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5700397A (en) * | 1992-06-16 | 1997-12-23 | Fuji Oil Co., Ltd. | Emulsifier, emulsion composition, and powder composition |
US5603961A (en) * | 1992-10-01 | 1997-02-18 | Tanabe Seiyaku Co., Ltd. | Sustained release multi-core microsphere preparation and method for producing the same |
US5378413A (en) * | 1993-01-21 | 1995-01-03 | The United States Of America As Represented By The Secretary Of The Navy | Process for preparing microcapsules having gelatin walls crosslinked with quinone |
US6019998A (en) * | 1993-05-18 | 2000-02-01 | Canon Kabushiki Kaisha | Membrane structure |
US5872140A (en) * | 1993-07-23 | 1999-02-16 | Research Institute For Medicine And Chemistry, Inc. | Vitamin D analogues |
US5993851A (en) * | 1993-07-28 | 1999-11-30 | Pharmaderm Laboratories, Ltd. | Method for preparing biphasic multilamellar lipid vesicles |
US5428014A (en) * | 1993-08-13 | 1995-06-27 | Zymogenetics, Inc. | Transglutaminase cross-linkable polypeptides and methods relating thereto |
US5827531A (en) * | 1994-12-02 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microcapsules and methods for making |
US5603952A (en) * | 1994-12-30 | 1997-02-18 | Tastemaker | Method of encapsulating food or flavor particles using warm water fish gelatin, and capsules produced therefrom |
US6020200A (en) * | 1995-03-03 | 2000-02-01 | Metabolex, Inc. | Encapsulation compositions and methods |
US5670209A (en) * | 1995-04-24 | 1997-09-23 | Brite-Line Technologies, Inc. | High brightness durable retro-reflecting microspheres and method of making the same |
US5780056A (en) * | 1996-05-10 | 1998-07-14 | Lion Corporation | Microcapsules of the multi-core structure containing natural carotenoid |
US5766637A (en) * | 1996-10-08 | 1998-06-16 | University Of Delaware | Microencapsulation process using supercritical fluids |
US6221401B1 (en) * | 1996-12-02 | 2001-04-24 | The Regents Of The University Of California | Bilayer structure which encapsulates multiple containment units and uses thereof |
US6325951B1 (en) * | 1997-01-31 | 2001-12-04 | Givaudan Roure Flavors Corporation | Enzymatically protein-encapsulating oil particles by complex coacervation |
US6039901A (en) * | 1997-01-31 | 2000-03-21 | Givaudan Roure Flavors Corporation | Enzymatically protein encapsulating oil particles by complex coacervation |
US6063820A (en) * | 1997-03-20 | 2000-05-16 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Medical food for diabetics |
US6630157B1 (en) * | 1997-07-22 | 2003-10-07 | Viatris Gmbh & Co. Kg. | Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
US6106875A (en) * | 1997-10-08 | 2000-08-22 | Givaudan Roure (International) Sa | Method of encapsulating flavors and fragrances by controlled water transport into microcapsules |
US6274174B1 (en) * | 1997-10-31 | 2001-08-14 | Nisshinbo Industries, Inc. | Aggregates of spherical multivalent metal alginate microparticles and methods of making them |
US6234464B1 (en) * | 1998-07-08 | 2001-05-22 | K.D. Pharma Bexbech Gmbh | Microencapsulated unsaturated fatty acid or fatty acid compound or mixture of fatty acids and/fatty acid compounds |
US6417233B1 (en) * | 1998-10-21 | 2002-07-09 | Sigma-Tau Healthscience S.P.A. | Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiguinones and methods of using same |
US6103378A (en) * | 1998-11-23 | 2000-08-15 | The Mead Company | Capsules having discrete solvent/color former and diluent capsule encapsulated phases |
US6534091B1 (en) * | 1999-07-02 | 2003-03-18 | Cognis Iberia S. L. | Microcapsules |
US6528165B2 (en) * | 1999-08-17 | 2003-03-04 | Luminex Corporation | Encapsulation of discrete quanta of fluorescent particles |
US6328995B1 (en) * | 1999-09-24 | 2001-12-11 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form and process for their production |
US6534094B2 (en) * | 2000-05-03 | 2003-03-18 | Eriochem S.A. | Manufacturing process of microcapsules for sustained release of water soluble peptides |
US20020031553A1 (en) * | 2000-05-03 | 2002-03-14 | Nora Moyano | Manufacturing process of microcapsules for sustained release of water soluble peptides |
US6365176B1 (en) * | 2000-08-08 | 2002-04-02 | Functional Foods, Inc. | Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy |
US6441050B1 (en) * | 2000-08-29 | 2002-08-27 | Raj K. Chopra | Palatable oral coenzyme Q liquid |
US20030091654A1 (en) * | 2000-09-21 | 2003-05-15 | Katz David P. | Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US6300377B1 (en) * | 2001-02-22 | 2001-10-09 | Raj K. Chopra | Coenzyme Q products exhibiting high dissolution qualities |
US20030044380A1 (en) * | 2001-07-19 | 2003-03-06 | Zhu Yong Hua | Adhesive including medicament |
US6544926B1 (en) * | 2001-10-11 | 2003-04-08 | Appleton Papers Inc. | Microcapsules having improved printing and efficiency |
US20030133886A1 (en) * | 2001-11-15 | 2003-07-17 | Xerox Corporation | Photoprotective and lightfastness-enhancing siloxanes |
US6652891B2 (en) * | 2001-12-12 | 2003-11-25 | Herbasway Laboratories, Llc | Co-enzyme Q10 dietary supplement |
US20050019416A1 (en) * | 2002-04-11 | 2005-01-27 | Ocean Nutrition Canada Ltd. | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US6974592B2 (en) * | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US20040106591A1 (en) * | 2002-11-22 | 2004-06-03 | Pacioretty Linda M. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
US6972592B2 (en) * | 2003-11-24 | 2005-12-06 | Lsi Logic Corporation | Self-timed scan circuit for ASIC fault testing |
US6969530B1 (en) * | 2005-01-21 | 2005-11-29 | Ocean Nutrition Canada Ltd. | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof |
US20070059340A1 (en) * | 2005-09-09 | 2007-03-15 | Anthony Bello | Omega-3 Fatty Acids Encapsulated In Zein Coatings and Food Products Incorporating the Same |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9226524B2 (en) | 2010-03-26 | 2016-01-05 | Philip Morris Usa Inc. | Biopolymer foams as filters for smoking articles |
US10264815B2 (en) | 2010-03-26 | 2019-04-23 | Philip Morris Usa Inc. | Biopolymer foams as filters for smoking articles |
DE102011018716A1 (en) * | 2011-04-26 | 2012-10-31 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Microcapsule useful for micro-encapsulation, comprises an outer sheath and a volume of an antifreeze agent, which is enclosed by the outer sheath |
WO2022055069A1 (en) * | 2020-09-10 | 2022-03-17 | 서울대학교산학협력단 | Multifunctional microcapsule composition and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
WO2004041251A1 (en) | 2004-05-21 |
ES2347045T3 (en) | 2010-10-25 |
BR0315977A (en) | 2005-09-20 |
DE60332958D1 (en) | 2010-07-22 |
JP4833553B2 (en) | 2011-12-07 |
CN1731983A (en) | 2006-02-08 |
KR101175774B1 (en) | 2012-08-21 |
HK1084054A1 (en) | 2006-07-21 |
EP1575561A1 (en) | 2005-09-21 |
ATE470436T1 (en) | 2010-06-15 |
CA2471821C (en) | 2006-04-25 |
MX272648B (en) | 2009-12-10 |
MXPA05004859A (en) | 2005-12-05 |
NZ539777A (en) | 2008-02-29 |
CA2471821A1 (en) | 2004-05-21 |
US20050067726A1 (en) | 2005-03-31 |
AU2003283101A1 (en) | 2004-06-07 |
BRPI0315977B1 (en) | 2018-04-03 |
KR20050084683A (en) | 2005-08-26 |
KR20110112481A (en) | 2011-10-12 |
US8900630B2 (en) | 2014-12-02 |
DK1575561T3 (en) | 2010-09-20 |
CN100536828C (en) | 2009-09-09 |
EP1575561B1 (en) | 2010-06-09 |
AU2003283101B2 (en) | 2008-12-11 |
US20110111020A1 (en) | 2011-05-12 |
JP2006506410A (en) | 2006-02-23 |
BRPI0315977B8 (en) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8900630B2 (en) | Microcapsules having multiple shells and method for the preparation thereof | |
JP5372310B2 (en) | Agglomeration of encapsulated microcapsules and production thereof | |
McClements et al. | Emulsion‐based delivery systems for lipophilic bioactive components | |
JP2005522313A5 (en) | ||
AU2006201070B2 (en) | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: DSM NUTRITIONAL PRODUCTS AG, SWITZERLAND Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:OCEAN NUTRITION CANADA LIMITED;REEL/FRAME:031246/0134 Effective date: 20130705 |